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Demyelinating diseases such as multiple sclerosis may be influenced by gender 
dimorphisms and sex hormones.  Here, the cuprizone model of toxin-induced 
oligodendrocyte death and demyelination was used to investigate sex differences in two 
mouse strains, SJL and C57BL/6.  The results indicate that female SJL mice are partially 
protected from oligodendrocyte loss and demyelination compared to their male 
counterparts.  No sex differences were exhibited in the C57BL/6 strain.  Furthermore, 
SJL mice exhibited differences in demyelination pattern and severity compared to 
C57L/6 mice, suggesting a genetic influence on responses to cuprizone intoxication.  In 
addition, the potential therapeutic benefit of estrogen was investigated by administration 
of 17β-estradiol (E2), at pregnancy levels, to mice during cuprizone intoxication.  
Interestingly, E2 was effective in partially reducing oligodendrocyte loss and 
demyelination.  This protection was accompanied by a delay in microglia accumulation 
as well as expression of the pro-inflammatory cytokine tumor necrosis factor alpha 
(TNFα) and the growth factor insulin-like growth factor -1 (IGF-1).  These studies 
indicate that estrogen signaling represents an attractive avenue for future studies into 
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1.1  Pathogenesis of Multiple Sclerosis 
 
Overview of presenting symptoms.  
 Multiple Sclerosis (MS) is a degenerative disease of the Central Nervous System 
(CNS) characterized by multiple focal inflammatory lesions to the white matter of the brain 
and spinal cord [1].  The varied location and severity of lesions leads to clinical symptoms 
which differ from patient to patient [1].  Among the most common initial symptoms are: 
monocular visual loss (optic neuritis), double vision (diplopia), weakness or decreased 
dexterity in one or more limbs, sensory disturbance, gait instability, and ataxia. Later in 
disease, bladder dysfunction, heat sensitivity and fatigue also occur in many patients. In 
advanced cases of MS cognitive deficits such as memory loss, impaired attention, and 
difficulties with problem-solving are also common.   
 In order to standardize diagnosis and reporting, the Advisory Committee on Clinical 
Trials of New Agents in MS of the National Multiple Sclerosis Society (NMSS) undertook a 
survey of the international MS clinical research community in an effort to develop a 
consensus on definitions and terminology which describe clinical outcomes and course 
patterns of MS patients [2].  This survey resulted in 4 categories of the clinical course of MS 
being defined: relapsing-remitting, secondary progressive, primary progressive, and 
progressive relapsing.  The most common form of MS is “relapsing-remitting” and is 
characterized by acute attacks of neurological symptoms (commonly referred to as 
“relapses”) which resolve partially or completely and are separated by periods of remission 
during which there is lack of disease progression.  Typically this pattern persists for many 
years, until the repair mechanisms diminish and the patient enters a stage of steady and 
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irreversible decline (with or without superimposed relapses) termed “secondary progressive”.  
A minority of patients (10-20%) initially present with a progressive decline that does not 
resolve and this form of MS is termed “primary progressive” if no relapses occur, or 
“progressive relapsing” if relapses are superimposed on the progressive decline. 
 
Histopathology of MS lesions.  
 Inflammation and myelin destruction are the primary hallmarks of the MS lesion.  
These plaques can occur anywhere in the white matter of the CNS, and may also occur in the 
gray matter [3].  The classically defined active lesion contains myelin sheaths in the process 
of dissolution and lymphocytes as well as infiltrating macrophages which contain myelin 
degradation products [4, 5].  In comparison, inactive lesions are relatively devoid of myelin 
and oligodendrocytes and contain only a few lymphocytes and macrophages at perivascular 
sites.  Demyelinated axons in the inactive lesions are embedded in astrocytic glial scar tissue.  
Due to the long duration of MS, it is rare that newly formed lesions are examined for 
pathological characterization.  However, recently, a few reports describing the cellular 
activity of early-stage lesions have been published. These reports indicate a role for primary 
oligodendrocyte dysfunction in the etiology of MS lesions, thus challenging the idea that all 
MS lesions are induced by autoimmune attack on myelin proteins.   
 In 2000, Lucchinetti and colleagues undertook an extensive examination of over 200 
actively demyelinating lesions from autopsy and biopsy derived MS tissue [6]. They 
concluded that MS lesions could be divided in to four types.  Patterns I and II were the most 
common and displayed the classical hallmarks of perivenous distribution, large demyelinated 
plaques and a dominance of macrophage and T cell involvement. These 2 subtypes of lesions 
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differed from each other only in the deposition of complement and antibodies, which occurs 
in pattern II.  Patterns III and IV also contained macrophages and T cells; however, these 
lesions differed from patterns I and II in that they contained evidence of oligodendrocyte 
apoptosis or perturbation.  Features of pattern III lesions which set them apart include: lack 
of immune cells centering around inflamed blood vessels, ill-defined lesion contours, 
significant oligodendrocyte apoptosis, and preferential loss of myelin-associated glycoprotein 
(MAG) compared to other myelin proteins.  Pattern III was detected mainly in tissue 
obtained with in 2 months of disease onset, leading to the conclusion that oligodendrocyte 
apoptosis may be an early stage of lesion formation. It is tempting to speculate that pattern I 
and II lesions might represent older and more developed lesions. However the lack of a 
follow up study of patients presenting with pattern III lesions left this possibility open-ended.  
Pattern IV lesions were relatively rare in this study, occurring in only 3 of the 200 patients 
with a variant of primary progressive MS.  Pattern IV lesions looked similar to patterns I and 
II, except for extensive loss of oligodendrocytes, lack of remyelination shadow plaques, and 
presence of DNA fragmentation in oligodendrocytes, indicating perturbation of 
oligodendrocytes.  
 Lucchinetti’s study is not the only report suggesting that newly formed MS lesions 
may be induced by oligodendrocyte death. In 2004, Barnett and Prineas described in intricate 
detail the lesion of a young patient who died within 17 hours of an acute attack, allowing the 
rare opportunity to study a very newly formed lesion [7].  Interestingly, this lesion was 
characterized by extensive oligodendrocyte apoptosis, the presence of activated microglia, 
relatively little loss of myelin sheaths, and absence of T cells and phagocytic macrophages.  
However, other older actively demyelinating lesions in this patient displayed the classical 
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pattern of T cell and phagocytosing macrophage involvement, suggesting that 
oligodendrocyte apoptosis in the absence of T cells may represent a very early stage of lesion 
formation in MS patients.  These authors were able to identify 9 other similar lesions in 6 out 
of 11 patients who also died shortly after an acute attack, whereas no apoptotic lesions of this 
kind were found in additional 6 patients with established chronic MS.  While intriguing, the 
reports of Lucchinetti and Barnett and Prineas remain controversial and the established 
dogma is that MS lesions are induced by immune attack against myelin antigens. 
   
   
1.2 Sex Differences in MS 
  
 A prevalence of disease susceptibility in the female is common to several 
autoimmune diseases including multiple sclerosis, rheumatoid arthritis, Grave's disease, 
systemic lupus erythematosus, myasthenia gravis, Sjogren's syndrome and Hashimotos 
thyroiditis [8, 9].  In MS, the most often reported sex ratio is two females per one male [10-
12].  Although subtle and not as widely accepted as a difference in susceptibility, there is also 
evidence that MS displays sex differences with respect to disease severity. A natural history 
study of greater than 1800 patients demonstrated that female gender was associated with a 
slower progression of disease [13]. In addition, MRI scans of 281 female and 132 male MS 
patients showed that men had a lower number of contrast-enhancing lesions, which represent 
areas of active inflammation, but a higher number of “black hole” lesions, which mark 
axonal loss [14].  This indicated that males with MS may be more likely to develop lesions 
that are less inflammatory, but result in greater axonal destruction.  Possible mechanisms for 
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sex differences include influences by sex hormones on the immune system and/or the CNS, 
influence of sex chromosomes or sex-dependant effects of allelic variants, microchimerism (a 
recently introduced suspect in autoimmunity), or some combination of the above. 
 
Immunological basis for sex differences.  
 On the whole, females exhibit more robust cell-mediated and humoral-mediated 
immune responses to antigenic challenges, such as vaccination and infection, compared to 
males [15].  Numbers of CD4+ T cells are higher in women [16] and T regulatory (TReg) cell 
numbers fluctuate with the ovarian cycle [17].  This may be important for autoimmune 
diseases, as TReg functional deficits have been implicated in MS and rheumatoid arthritis [18, 
19].  Furthermore, estrogen was shown to increase the expression and responsiveness of CC-
chemokine receptor 5 (CCR5) and CCR1 in CD4+ T cells, which has important implications 
for T cell homing [20].  A gender difference in the T helper 1/ T helper 2 (Th1/Th2) balance 
is one hypothesis offered by researchers to explain differences in autoimmune disease 
susceptibility or severity between the sexes.  
 MS is normally considered to be a Th1-mediated autoimmune disease based on the 
expression of Th1 cytokines interfereon gamma (IFNγ) and tumor necrosis factor (TNF) by 
myelin antigen-specific T cells isolated during active disease [21-24].  In one study, freshly 
isolated PBMC from MS patients stimulated with various control and myelin antigens 
revealed an IFNγ (Th1) skewing in females and an interleukin 5 (IL-5) (Th2) skewing in 
males [25, 26].  Sex differences could also be mediated through innate immune cells such as 
microglia and macrophages that also secrete pro- and anti-inflammatory molecules, and may 
be involved in the pathology of MS [27-29].  The effects of estrogen on innate immune 
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responses are generally repressive [30]. In particular, in vitro administration of estrogen 
reduced the production of pro-inflammatory cytokines IL-1β, IL-6, and TNFα in 
macrophages [31] and nitric oxide (NO) and TNFα in microglia (reviewed in [29]). 
 
Microchimerism.  
 Microchimerism is the stable presence of a small number of non-host cells in an 
individual. Microchimerism can develop as a consequence of maternal-fetal and fetal-
maternal transmission of haematopoeitic cells through the placenta.  Fetal DNA has been 
detected in women for as long as 27 years following the birth of their last child [32] and 
maternal cells have been detected in adult offspring up to 28 years of age [32, 33].  Other 
avenues of developing microchimerism include: blood transfusion, bone-marrow or organ 
transplant, and twin gestation. Within the last few years, there has been interest in the 
concept of linking microchimerism to autoimmunity [34]. While there is some evidence for 
increased microchimerism in a few autoimmune diseases, notably systemic sclerosis, the 
correlation remains vague for many others (reviewed in [35]).  The incidence of 
microchimerism in MS patients has not been studied directly.  However, given that 
microchimerism is common in women who have given birth, a logical assumption is that if 
microchimerism is a risk factor for the development of MS, then women who have given 
birth should have a higher incidence of MS.  To the author’s knowledge, only two studies 
have addressed this and have indicated that neither pregnancy [36], nor bearing children from 
more than one father [37] is a risk factor for developing MS.  Therefore, there is no 
convincing evidence to date that fetal-maternal microchimerism plays a role in the female 
preponderance of MS susceptibility.  
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Chromosomal influence.  
 Recently, an elegant study by the Voskuhl group demonstrated the importance of sex 
chromosome makeup in animal models of MS and lupus [38]. In male mammals, the Y 
chromosome –linked gene Sry is responsible for testes development and subsequent 
determination of the male sex.  This was shown by experiments in which expression of an 
Sry transgene in an XX mouse resulted in testes development [39] and deletion of Sry from 
the Y chromosome (Y-) led to ovary development [39]. A model system has been developed 
using these Y- mice in which Sry was added back as a transgene on an autosome to produce 
XY-Sry males [40].  When bred to normal XX females, four genotypes were produced: XX 
and XY- ovary-bearing females, and XY-Sry and XX Sry testes-bearing males [41].  The end 
result of these genetic manipulations was the ability to study the effect of the sex 
chromosome makeup on the background of both female and male hormones.  Using this 
model in SJL mice, Smith-Bouvier and colleagues [38]  assessed the influence of sex 
chromosome makeup in two distinct animal models of autoimmune disease, experimental 
autoimmune encephalomyelitis (EAE) and pristane-induced lupus, both of which are known 
to display increased susceptibility in SJL females [42, 43].  The results indicated that the XX 
chromosome makeup produces more severe disease compared to XY- in mice that developed 
on both the female and male hormonal background, in both autoimmune models.  However, 
this does not rule out an additional effect of sex hormones, because the authors performed 
these experiments on gonadectomized animals, to avoid any masking of the chromosome 
influence.  Interestingly, similar experiments using the EAE model in C57BL/6 mice, which 
do not display gender differences in EAE [44-46], did not show any difference in XX or XY- 
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chromosomal makeup, revealing an interaction between sex chromosome makeup and 
genetic background [38]. 
 
Parental effects.  
 Evidence supporting a parent-of-origin effect, whereby the sex of the affected parent 
would influence the risk of developing MS in offspring, has been controversial.  In 2004, 
Hupperts and colleagues studied concordant parent-child families with MS and concluded 
that there was no evidence for a parent of origin effect distorting sex ratios in affected 
offspring [47]. However they did report a potential effect on disability and disease course in 
offspring.  Since then, some studies have shown an increased risk from an affected father 
[48], conversely an affected mother [49, 50], or no effect based on the sex of the affected 
parent [51].   
 
Allelic variation.  
 Allelic variants in several genes have shown sex-dependent associations with MS 
susceptibility.  Gene polymorphisms in IFNγ were associated with susceptibility to MS in 
males but not females [52-56].  Brain-derived neurotrophic factor (BDNF) is another gene 
for which allelic variation showed a sex-dependent influence on MS susceptibility [57].  In 
this study of a Polish population with a relatively small sample size, one polymorphism of 
BDNF was associated with increased risk for MS in both males and females, while another 
was associated with increased risk only in females. In addition, the AT haplotype on 
chromosome 16 chemokine cluster was indicated to be protective to MS susceptibility in 
males but not females [58].  A polymorphism in the IL-4 promoter (-589C/T) was associated 
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with MS in females but not males [59].  Analysis of a polymorphism in the matrix 
metalloproteinase-9 (MMP-9) promoter (-1562C/T) indicated a protective effect of the T 
allele for MS susceptibility only in females of a Serbian population[60].  However, a similar 
analysis of a Swedish population indicated no influence of MMP-9 polymorphisms in MS 
susceptibility.   The mechanism for how these polymorphisms may contribute to sex 
differences in susceptibility are not known; however, one hypothesis which remains to be 
tested is that the polymorphisms may alter binding of sex hormone transcription factors and 
thus alter gene expression in a sex-dependent manor. 
 
1.3 Sex Differences in Animal Models of Demyelination 
 
Experimental autoimmune encephalomyelitis (EAE).  
 EAE, the dominant animal model of MS, is induced by immunization with myelin 
proteins or T cells that have been primed to myelin proteins and adoptive transferred into 
susceptible hosts [61].  The resulting pathology is similar to that seen in MS, with 
demyelinated lesions in the spinal cord and brain highly infiltrated with inflammatory 
macrophages and T cells.  Disease severity of the rodent is measured by varying degrees of 
limb or tail paralysis.  Sex differences occur in EAE, and these vary by strain, suggesting a 
genetic influence.  Sex differences in the course of EAE disease progression were first 
reported in Lewis rats, in which females but not males exhibited relapses [62].  Similarly, 
female SJL mice have also demonstrated a relapsing disease course compared to a 
monophasic course in males, as well as increased susceptibility and severity of EAE [42, 63, 
64]. This sex difference has been attributed in a large part to differences in male and female 
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T cells during the induction phase of the disease as well as the influence of sex hormones on 
Th1/Th2 cytokines [65-67].  In addition, a comparison of seven different mouse strains 
immunized with various myelin peptides demonstrated that female SJL and ASW mice 
displayed greater disease severity, whereas disease was more severe for males of the B10.PL 
and PL/J strains [46].  Female SJL and NZW had increased disease incidence compared to 
male counterparts, but C57BL/6 and NOD mice did not exhibit any sex differences [46].  
Thus, in EAE, the effect of sex appears to be specific to particular strains of mice and it is not 
reflected specifically on the type of immune T cells or antigenic peptide. 
 
Theiler’s murine encephalomyelitis virus model.  
 Intracerebral inoculation of rodents with Theiler’s murine encephalomyelitis virus 
(TMEV) leads to an acute encephalomyelitic phase followed by a chronic demyelination 
phase [68].  Demyelinated lesions of the spinal cord exhibit infiltration primarily of T cells, 
some macrophages, and a few B cells and plasma cells (reviewed in [68]).  Functional 
deficits such as hind limb paralysis, spasticity, ataxia, and incontinence mirror those 
described in MS [68].  In the Theiler’s virus model, both male and female SJL male mice are 
highly susceptible to disease development, however, it has been reported that males exhibit 
more severe neurological deficits during the chronic phase of disease, possibly due to lower 
levels of anti-viral IgG antibodies and increased infectious virus titers in males compared to 
females during the acute phase of disease [69]. In the C57L/J strain, male mice are 
susceptible to disease formation, but females are completely resistant, which was shown to 
be correlated with increased anti-viral responses in female mice [70].  Thus, in TMEV, two 
strains of mice show sex differences in symptoms or resistance to disease. 
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Toxin models of demyelination.  
 Toxin-induced demyelinating lesions offer a reproducible model for studying 
oligodendrocyte loss and remyelination without the complication of autoimmune induction.  
In the ethidium bromide demyelination model injection of ethidium bromide into the caudal 
cerebellar peduncles creates a focal area of demyelination that undergoes spontaneous 
remyelination [71, 72].  Comparisons of remyelination in young and old male and female rats 
revealed an age-dependent sex difference, in that young male and female rats remyelinated 
similarly, but older females remyelinated more efficiently than older male counterparts [73].  
This sex difference in remyelination was not due to circulating gonadal steroids, as castration 
did not affect remyelination in young or old rats of either sex.  Despite this, a role for gonadal 
hormones has been suggested due to the fact that progesterone administration induced a 
slight increase in remyelination in older male rats [74].  For cuprizone intoxication, a model 
which will be discussed in detail later, no direct comparisons of sex differences have been 
reported. 
  
1.4 The Role of Sex Hormones in MS and Animal Models of Demyelinating Disease. 
  
 Sex steroid hormones that circulate in the blood are produced in the adrenal glands as 
well as the ovaries of premenstrual women, and testes of men [75].  In addition, many cell 
types in various tissues of the body, including the brain, have the ability to metabolize sex 
hormone precursors, or produce them de novo from cholesterol [76].  Sex steroids are formed 
by a series of conversions by steroidogenic enzymes [77].  Synthesis begins with conversion 
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of cholesterol to pregnenalone in the mitochondria by the cytochrome P450ssc enzyme (scc 
for side-chain cleavage).   Pregnenalone is then metabolized to progesterone, which can be 
further metabolized to testosterone, and finally to 17β-estradiol by the enzyme aromatase.   In 
addition to 17β-estradiol (estradiol, E2), there are two other biologically active estrogens in 
mammals: estrone (E1), and estriol (E3) [75].  The most abundant and potent estrogen in 
premenopausal women is estradiol, with estrone production by nonovarian tissues becoming 
the predominant source of estrogen in postmenopausal women [75].  Estrone can be 
converted to estradiol in the ovaries or other target tissues [75].  Estriol is produced by the 
metabolism of estrone and estradiol and becomes important mainly during pregnancy where 
it is produced by the placenta and is at that time the most abundant estrogen in maternal 
circulation [75].  Though estrogens and progestins are considered “female” hormones, and 
testosterone a “male” hormone, all three are produced in both genders.   
 
Sex hormones in MS. 
 A role for sex hormones in MS was suggested by the observation that disease may be 
altered by pregnancy.  This observation was confirmed in a large prospective study which    
demonstrated a decrease in disease relapse rate during the third trimester of pregnancy (when 
sex hormone levels are high) [78]. Furthermore, the relapse rate was significantly increased 
in the first three months post-partum, when hormone levels drop, then returned to the pre-
pregnancy rate [78]. Interestingly, a clinical trial of a small number of MS patients showed 
that taking a dose of oral estriol sufficient to mimic the levels seen during pregnancy 
decreased active lesions (as seen by MRI) compared to pre-treatment baselines in relapsing-
remitting patients [79]. Estriol treatment also reduced the delayed-type hypersensitivity 
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response to tetanus in these patients and reduced expression of IFNγ from isolated peripheral 
blood mononuclear cells (PBMCs) [79].  Furthermore, PBMCs collected from these patients 
and stimulated ex vivo indicated that estriol treatment led to increased production of the anti-
inflammatory cytokines IL-5 and IL-10 and decreased production of the pro-inflammatory 
cytokine TNFα [80].  The somewhat paradoxical observation that women are more 
susceptible to MS and yet it is ameliorated during pregnancy when female hormones are 
high, may be explained by a estrogen’s biphasic effect on the immune system.  Low 
concentrations of estrogen facilitate cell-mediated immunity, but high concentrations, such as 
during pregnancy, inhibit cell-mediated immunity [81].   
 Though the age of onset of MS in women tends to be during early adulthood (ages 
18-30) the onset in men is slightly later (ages 25-40) which corresponds with the beginning 
of the decline in bioavailable testosterone [82-84]. This observation may indicate that 
testosterone has a protective effect in young males [79].  Recently, a small clinical trial in 
male MS patients demonstrated that one year of testosterone administration improved 
cognitive performance and slowed brain atrophy, but did not affect the number or volume of 
contrast-enhancing lesions [85].  A conclusion for an anti-inflammatory role of testosterone 
could not be made in this study, since the male patients enrolled had a relatively low level of 
baseline inflammation as measured by MRI.  However, the results of this study do indicate a 
neuroprotective function for testosterone. 
  
Effects of estrogen on EAE. 
 Additional evidence linking sex steroids to autoimmune demyelinating disease has 
been gleaned from the EAE model. For example, female Lewis rats treated with the synthetic 
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estrogen 17α-ethinylestradiol (EE) beginning 4 days before disease induction and continuing 
through the disease course reportedly experienced a partial suppression of EAE symptoms, as 
well as a reduction in spleen and thymus weights [86].  Castration of female B10.RII mice 
led to earlier onset of EAE, whereas administration of pregnancy levels of estradiol or estriol 
delayed onset [87].  Since these initial studies were published, several other studies have also 
demonstrated the beneficial effects of estrogens in EAE in several rodent strains, and leant 
support to the hypothesis that estrogen mediates a Th1 toTh2 immune shift.  For instance, 
estriol-mediated reduction of EAE severity in female SJL mice was associated with increased 
production of serum IgG1 and splenocyte secreted IL-10 (Th2 associated phenomenon), but 
it did not change splenocyte production of IL-2, IL-5 or IL-10 [66].  Another study 
demonstrated that estriol ameliorated disease in male as well as female C57BL/6 mice, and 
led to suppression of several Th1 associated pro-inflammatory cytokines (TNFα, INFγ, IL-2, 
IL-6) from stimulated splenocytes of both genders as well an increase in the Th2-associated 
cytokine IL-5 from male splenocytes [45].  Furthermore, estradiol limited behavioral 
impairment and inflammation in female rats [88].  Interestingly, even low doses of estradiol 
and estriol reduced EAE severity in male and female SJL and female B10 mice, but only if 
administered before disease onset [89]. This study also demonstrated that estrogen treatment 
led to a reduction in IFNγ, IL-12 and TNFα production by stimulated lymph node cells or 
splenocytes, as well an increase in IL-10, although the results did not reach statistical 
significance.  In summary, both estriol and estradiol appear to down-modulate peripheral 
immune responses and have a beneficial affect when administered before the onset of 
symptoms. 
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 In addition, estradiol treatment led to a significant reduction in recruitment of 
macrophages and T cells into the CNS as well as a reduction in the percentage of these cells 
that produced TNFα, however, it did not have a significant influence on the production of 
TNFα by resident microglia [90].  The potential importance of a regulation of TNFα is 
demonstrated by the finding that EAE severity is significantly diminished in TNFα-deficient 
mice [91].  Interestingly, the ability of estradiol to reduce EAE severity was not altered in 
IFNγ, IL-10 or IL-4-deficient mice.   Thus, estradiol appears to primarily affect the number 
of immune cells in the CNS and their production of TNFα.  
 The use of estrogen receptor-deficient mice and selective agonists led to the finding 
that estradiol’s ability to reduce inflammation and EAE symptoms is mediated by the alpha 
estrogen receptor (ERα) and not the beta estrogen receptor (ERβ) [92, 93].  Furthermore, 
using T cell-deficient mice or chimeras, it was determined that this effect of estradiol was not 
mediated through ERα in T cells, but instead must be another, as yet undetermined, cell type 
[94, 95].  The chemical production of estrogen receptor-specific agonists has further 
increased knowledge of the role of ERα and ERβ in demyelinating disease.  Recently, use of 
the ERβ agonist diarylpropionitrile (DPN) confirmed that signaling through ERβ did not 
reduce EAE clinical scores or reduce inflammation during the time frame of disease 
generally studied, however, it did decrease symptoms later in disease [96].  In addition, both 
ERα and ERβ ligands exhibited neuroprotective effects by reducing neuronal loss in the gray 





Effects of progesterone on EAE 
 The data on progesterone in EAE is somewhat conflicting.  Recently, two doses of 
continuously administered progesterone, beginning one week prior to active EAE induction 
(leading to a 10-fold or 20-fold increase in serum levels) were shown to have protective 
effects in female C57BL/6 mice, generating a slight delay in disease onset and reduction of 
clinical scores [97].  Histologically, progesterone treatment during EAE resulted in a 
decrease of infiltrating inflammatory cells and a preservation of myelin proteins.  In contrast, 
administration of progesterone beginning 4 days prior to active EAE induction (resulting in a 
10-fold increase in serum levels) in female Lewis rats led to an increased severity of 
sensorimotor deficits, cell death in the gray and white matter, and increased accumulation of 
inflammatory cells [88]. Progesterone administration at two different doses had no effect on 
adoptive transfer of T cell-induced EAE in female SJL mice when administered continuously 
beginning three weeks before disease induction [66].  However, serum levels of progesterone 
were not confirmed in these mice, making comparisons to other experiments difficult.  
Therefore, it is not clear whether progesterone has a beneficial affect and if it does, it appears 
to be minimal. 
 
Effects of testosterone on EAE. 
 Several studies have shown benefits of testosterone on demyelinating disease.  Male 
SJL mice exhibit less severe EAE compared to females [42, 46, 63, 64].  Interestingly, 
castration of male SJL mice was shown to increase EAE severity, suggesting that 
testosterone has a protective effect [65, 98]. However, castration did not alter disease in 
C57BL/6, a strain which does not display sex differences in EAE [98].  Administration of 
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testosterone one week prior to EAE induction, at a dose which resulted in a 10-fold increase 
in serum levels, resulted in reduced disease severity in males of both the SJL and C57BL/6 
strains [98].  Similarly, administration of testosterone to female SJL mice two weeks prior to 
EAE induction resulted in reduced clinical symptoms and also increased production of the 
anti-inflammatory cytokine IL-10 by T cells [99].  Thus, it appears that the role of 
endogenous testosterone may be strain dependent, and that similar to estrogen, high doses of 
testosterone may provide a protective effect during EAE.    
 
1.5 The Role of Sex Steroids in Brain Glial Cells.  
 
Cells of the CNS may be influenced directly by circulating hormones in the blood 
stream, or they can metabolize these hormones to active steroid derivatives (reviewed in [76, 
77, 100]).  In addition, the proteins necessary to perform de novo synthesis of steroids 
directly from cholesterol have been demonstrated to be upregulated after brain injury [101-
107].  Furthermore, steroid signaling can occur through multiple mechanisms.  The classical 
mechanism of steroid action is through binding of the ligand binding domain on steroid 
hormone receptors, which act as transcription factors to modulate gene expression.  Steroids 
have been shown to exert rapid “non-genomic” effects such as modification of intracellular 
levels of calcium [108-110] or regulation of the activity of kinases, influencing signaling 
pathways such as the phosphoditidylinositol 3-kinase/protein kinase B (PI3K/Akt) [111] and 
mitogen-activated protein kinase (MAPK) pathways [112, 113].  It is plausible that synthesis 
of steroids in the CNS may differ among gender and in different strains of mice. For instance, 
3β-hydroxysteroid dehydrogenase-1 (3β-HSD-1), the enzyme which converts pregnenalone 
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to progesterone, was found to have reduced mRNA levels in female hypothalamus compared 
to male mice [114].  In addition, the regional distribution of aromatase (which converts 
testosterone to estradiol) mRNA was found to be similar in male and female rats, however, 
the number of aromatase expressing cells in each region was lower in the females [115]. 
 
Sex steroid receptor expression..   
 The current knowledge of expression of steroid hormone receptors in neurons or glial 
cells has been reviewed recently by Garcia-Ovejero and colleagues [116] and will be 
summarized below in addition to a few reports which have come out since that time.  In vitro 
studies indicate that all brain cell types (neurons, astrocytes, oligodendrocytes and microglia) 
express both estrogen receptors ERα and ERβ (reviewed in [116]) and that astrocytes also 
express the progesterone receptor (PR) and androgen receptor (AR) in vitro [117].  In vivo 
co-localization in subpopulations of neurons has been identified for ERα, ERβ, AR [118, 
119], and PR [120].  Astrocytes have been co-localized in vivo with ERα, ERβ, AR 
(reviewed in [116]); and PR [121]. ERβ is expressed in oligodendrocyte cell bodies and the 
myelin sheath in vivo [122, 123].  Furthermore, oligodendrocytes express AR in primates 
[124], but there is as yet no convincing in vivo co-localization of ERα or PR. In vivo 
evidence for steroid hormone receptors in microglia is more sparse, however, adult microglia 
isolated ex vivo have been shown to express ERα mRNA and in vivo by electron microscopy 
[125].  Moreover, ERβ and AR were detected in microglia after brain injury [126, 127].  
Many of these studies revealed that the steroid hormone receptors are expressed differentially 
in various brain areas, and were regulated in response to a variety of stimuli.  Therefore, it is 
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important to determine exactly which receptors are expressed in the cells of the region of 
interest and under the specific parameters of any experiment. 
 
 
Sex steroid functions in myelination and inflammation 
 
 Sex steroids have been shown to provide trophic and protective functions in the CNS 
and PNS and have the potential to affect the processes of demyelination, remyelination and 
axonal damage in MS [77, 100, 128].  While much is known about the effects of sex steroids 
on peripheral myelin and, in particular, the role of progesterone and its derivatives on 
peripheral myelination [129], the effects of sex steroids on central myelin and 
oligodendrocytes have been less well studied.  The following sections below review the 
effects of sex steroids on particular glial cells of the CNS, with specific emphasis on 
myelination and inflammation. 
 
Sex steroid effects on oligodendrocytes. 
  In 1966, Curry and Heim reported that estrogen administration causes an increase in 
myelination of neonatal rat brain [130]. Comparisons of oligodendrocyte progenitors from 
male versus female neonatal rat brains revealed increased yields of oligodendrocytes in 
female cultures [131].  Furthermore, studies of cultured oligodendrocytes and rat cerebellar 
organotypic cultures demonstrate that myelin basic protein (MBP) expression was enhanced 
upon administration of estradiol or progesterone [117, 132] and that estradiol promoted 
proliferation of OPCs as well as membrane sheet formation, while progesterone treatment 
increased cellular branching [131].   
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In addition, estradiol was shown to protect primary oligodendrocyte cultures from 
cytotoxic death induced by a peroxynitrite free-radical donor, and this effect was mediated by 
ERs, though no further mechanism was elucidated [133].  However, a recent study 
demonstrated that estradiol prevented hyperoxia-induced death of primary oligodendrocytes 
by regulating several mediators of apoptosis [134].  This group found that estradiol prevented 
hyperoxia-induced proapoptotic Fas-upregulation and caspase-3 activation as well as 
antagonized the inactivation of key kinases of the mitogen activated protein kinase (MAPK) 
and phosphatidylinositol 3-kinase (PI3K) cell survival promoting pathways.  In vivo, 
estradiol attenuated the loss of MBP in rat pups exposed to oxygen [134].    A role for sex 
hormones in remyelination is indicated by the finding that progesterone administration 
increased remyelination after toxin-induced demyelination in older male rats; however, the 
mechanism for this was not elucidated [74].      
 
Sex steroid effects on microglia and astrocytes.   
 Sex steroids appear to inhibit microglia activity.  In vitro studies with the N9 
microglia cell line indicated that estradiol, but not progesterone, attenuated superoxide 
release, phagocytic activity, and inducible nitric oxide synthase (iNOS) protein expression, 
and these effects were dependent on ER binding [135].  Furthermore, estradiol induced rapid 
phosphorylation of MAP kinase and a MAP kinase inhibitor blocked the anti-inflammatory 
effects of estradiol.  However, another study indicated that not only did estriol and estradiol 
have anti-inflammatory effects, but progesterone also reduced NO and TNFα in N9 cells. 
[136].  In the BV-2 microglia cell line, which expresses ERβ and not ERα, estradiol 
treatment led to a decrease in LPS-induced NO production, but in contrast to the reports for 
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N9 cells, it increased TNFα mRNA [137].  It is not known why estradiol produced the 
unexpected increase in TNFα mRNA, and could be a peculiarity of the BV-2 cell line.  
 Studies with primary microglia cultures activated by LPS indicated that estradiol 
reduces production of the inflammatory mediators iNOS, prostaglandin-E2 and matrix 
metalloproteinase 9 (MMP9) [138] and that estriol and progesterone reduced nitrite 
production [136].  In an in vivo model of brain inflammation (induced by 
intracerebroventricular injection of LPS), systemic estradiol administration inhibited 
morphological activation of microglia and infiltration of macrophages into the brain [139].  
Using estrogen receptor-deficient mice, it was demonstrated that ERα, but not ERβ, mediated 
this anti-inflammatory affect and was associated with a decrease in mRNA expression of 
MMP-9 [139].  Thus, in primary microglia, ERα may be an important mediator of anti-
inflammatory effects induced by estradiol. 
 The role of sex steroid modulation of inflammation in astrocytes is less well studied.  
Astrocyte cultures derived from neonatal mouse midbrain or cortex displayed regional 
differences in response to sex steroid modulation of TNFα.  Estrogen reduced TNFα in 
astrocytes from the midbrain but not cortex-derived astrocytes in response to LPS [140].  
More recently, astrocytes given ERβ agonist reduced IL-1β, TNFα and MMP-9 but ERα 
agonist only attenuated IL-1β [141].  Similar analyses were conducted on microglia and it 
was concluded that compounds that bind ERβ are more effective at attenuating pro-





1.6 The Cuprizone Model of Demyelination 
 
Mechanism of cuprizone action.  
 Cuprizone (biscyclohexanone oxalydihydrazone) is a copper chelator originally 
produced for use in clinical chemistry.  It is presumed, although not proven, that cuprizone’s 
effects in vivo are due to copper binding and preventing the availability of copper for 
biochemical processes.  In support of this, cuprizone intoxication resulted in strong inhibition 
of enzymatic activity of the copper-dependent enzymes monoamine oxidase and cytochrome 
oxidase in the brain [142], and cytochrome oxidase in liver [143].  Enlarged mitochondria 
were detected in oligodendrocytes and hepatocytes of cuprizone-treated animals, indicating a 
perturbation to mitochondrial function [144-146].  Recently, it was shown that 3 and 6 weeks 
of cuprizone treatment diminished the activities of complex I-III and II-III of the respiratory 
chain from mitochondria isolated from brain tissue [147].  Therefore, it is presumed that the 
toxic effects of cuprizone to oligodendrocytes are due to perturbation of mitochondrial 
function (reviewed in [148]).  Why the oligodendrocytes are more sensitive to cuprizone 
toxicity than other cell types is not known, but could be due to their high metabolic demand 
in order to maintain the extensive myelin sheath. 
 
Historical perspective. 
 Studies of cuprizone in animals were first performed in 1955 to study the systemic 
effects of copper chelation [149].  Dietary administration of 0.5% cuprizone for 7 weeks to 
male weanling mice was shown to produce severe brain edema characterized by vacuole 
formation, hydrocephalus, and demyelination [150].  Many of the subsequent studies focused 
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on the status spongiosis and astrocytosis which developed, though perturbations to myelin, 
oligodendrocytes, and axons were noted [145, 151].  Detailed ultrastructural studies of 
cuprizone-induced demyelination and remyelination in the superior cerebellar peduncle were 
first performed by Blakemore in the early 1970s [152-154].  In these studies, weanling male 
ICI mice were fed 0.5% cuprizone for up to 5 to 8 weeks to study demyelination and 6 or 7 
weeks followed by 2 or 4 weeks of recovery to study remyelination. Degenerating 
oligodendrocytes were reported at weeks 2 through 4, with almost no oligodendrocytes 
present by 5 weeks of cuprizone treatment.  The presence of phagocytosing migroglia and 
astrocytes were reported to be significantly increased at 3 and 4 weeks, while at 5 weeks, 
large areas of demyelinated axons were present, especially in the superior cerebellar 
peduncle which was 90% demyelinated.   
 Remyelination is also an important feature of this model.  At the same time as 
demyelination, the appearance of remyelinating oligodendrocytes was also noted at 5 weeks 
[154].  Two weeks of recovery from cuprizone after 7 weeks of intoxication resulted in 20% 
remyelination, whereas 4 weeks of recovery lead to 80-90% remyelination [154].  In another 
study, weanling male Swiss mice fed 0.6% cuprizone were reported to undergo consistent 
demyelination of superior cerebellar peduncle, with oligodendrocyte degeneration, 
accumulation of microglia, astrocytes and immature oligodendrocytes, and remyelination 
beginning within one week after removal of cuprizone from the diet [146].  These changes 
occurring with cuprizone intoxication did not result in breakdown of the blood-brain barrier 




Strain differences.  
 From the early studies of cuprizone intoxication, it was noted that mice were more 
susceptible than rats or guinea pigs [157], and that even within the same strain, mice 
maintained at separate facilities displayed marked differences in tolerance to cuprizone [158]. 
FGF2 KO on a 129 Sv-Ev:Black Swiss background required 0.3% cuprizone to induce 
demyelination compared to C57BL/6  mice that demyelinate with just 0.2% cuprizone [159]. 
BALB/cJ mice treated with 0.2% cuprizone along with C57BL/6 mice revealed a similar 
pattern of demyelination in the corpus callosum, but less demyelination and more microglia 
activation in the cortex as compared to C57BL/6 [160].  Lastly, 129SvJ mice required only 
0.1% of cuprizone to induce demyelination at week 5 (Matsushima, personal 
communication).  The results from these studies highlight the importance of titrating the 
cuprizone dose for each new strain that gives optimal demyelination while limiting systemic 
toxicity.   
 
Cuprizone-induced demyelination/remyelination in C57BL/6 mice. 
 The advent of transgenic and knockout mice provides a significant advancement for 
the study of demyelination and remyelination.  It is imperative to standardize the genetic 
background of mice so that comparisons among genetic mutants can be assessed for relative 
importance and function.  Since a majority of mutant mice are bred to the C57BL/6 
background, characterizing the effects of cuprizone on this strain became highly desirable.  
In the past decade, cuprizone intoxication and demyelination/remyelination of the corpus 
callosum white matter has been characterized by Matsushima and colleagues for the 
C57BL/6 mouse strain [148, 161]. Using a 0.2% cuprizone dose (which mitigates the 
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substantial weight loss, mortality and liver toxicity reported for the higher doses used in 
earlier studies [161]), these mice experienced demyelinating lesions of the corpus callosum, 
oligodendrocyte loss, active gliosis and accumulation of oligodendrocyte precursors [161, 
162].  During the first week of cuprizone treatment, the gene expression of several myelin 
proteins, including myelin-associated glycoprotein (MAG), myelin basic protein MBP), and 
ceramide galactosyltransferase (CGT), was drastically reduced [163].  The second and third 
weeks of treatment were characterized by the onset of oligodendrocyte cell death and the 
appearance of astrocytes and microglia/macrophages [161, 162].  By 5 weeks of treatment, 
nearly all of the mature oligodendrocytes were depleted from the midline corpus callosum, 
and there was a 90% reduction of myelinated axons [164]. Oligodendrocyte precursors were 
detected in the lesion during the first few weeks of demyelination, and increased to maximal 
levels at 4 and 5 weeks, after which these populations declined, presumably due to their 
differentiation to mature oligodendrocytes [162, 165].  
 Partial remyelination was achieved at 6 weeks, during continued intoxication, but was 
not sustained unless the toxin was removed from the diet [166].  Remyelination was near 
complete after 4 to 6 weeks off cuprizone treatment [163, 166].   Many cytokines and growth 
factors were produced in the demyelinated lesion during this process and several, specifically 
interleukin 1β (IL-1β), insulin-like growth factor 1 (IGF-1), and TNFα, have been shown to 
be important in the repair process [164, 165, 167]. 
 One advantage of the cuprizone model as characterized by Matsushima and 
colleagues is that it produces a stereotypical pathological pattern, allowing for quantified 
comparisons of temporal data sets.  In addition, it allows for the study of primary 
oligodendrocyte death and recovery, in an environment free of T cells involvement [165, 
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168] and other immunological complications.   However, although this model has been used 
extensively to study the cell types and cytokines involved in the process of demyelination 
and remyelination in male C57BL/6, much less is known about the cuprizone response of 
female C57BL/6 mice. In fact, to the author’s knowledge, no comprehensive gender 
comparisons have been made in any mouse strain treated with the cuprizone intoxication 
model.  The little that is known regarding cuprizone intoxication in female mice is discussed 
below. 
 
Gender differences in the cuprizone model. 
 Historically, early cuprizone studies were carried out in male mice, although there 
were some reports published using female mice also. Ludwin and colleagues exposed female 
Swiss mice to cuprizone but reported that they appeared not to be susceptible to cuprizone-
induced demyelination [146]. Elsworth and Howell cited using equal ratios of male and 
female albino mice for their studies, but did not note whether any gender differences were 
observed [158].  Female BSVS weanlings were used for cuprizone studies, but only 
spongiosis was analyzed, not demyelination [169].  
 Perhaps because of the lack of scientific evidence using female mice, the vast 
majority of cuprizone-induced studies since these earlier studies have also been performed in 
male mice. It was noted in early studies of C57BL/6 mice that females did undergo 
cuprizone-induced demyelination [148], however, data from female mice were not published.  
Since this report, several investigators in the last few years have used female mice for 
cuprizone-induced demyelination studies [170-175] without full knowledge of the temporal 
pattern of demyelination or the cellular profiles.  Most recently, two studies examining 
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cuprizone-intoxication on knockout mice backcrossed to the C57BL/6 background reported 
treating and combining data from male and female mice [176]. In both these studies it was 
noted in the text that no gender differences were observed.   
 
 Given the importance of sex differences and sex hormones in MS, it is critical that we 
gain a better understanding of the role of gender and sex hormones in the demyelination and 
remyelination processes.  A toxin model of primary oligodendrocyte death and demyelination 
may provide important insights to complement the work being done in autoimmune models 
of MS.  The first part of this dissertation work focuses on sex differences in the cuprizone 
model.  With the use of two different mouse strains, SJL and C57BL/6, we demonstrate that 
sex differences are dictated by the genetic background of the strains.  Furthermore, we find 
that the pattern of demyelination differs between the strains in location and in the rate at 
which demyelination occurs.  While it is possible that several hormones or derivatives may 
have an effect on demyelination or remyelination in the cuprizone model, the fourth chapter 
of this dissertation is focused on the influence of estradiol in modulating oligodendrocytes 
and demyelination.  It was demonstrated that estradiol administration attenuated cuprizone-
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 The role of mouse strain and the influence of gender on demyelination was explored 
for the first time in SJL mice using the cuprizone intoxication model.  We document here that 
SJL mice display a unique pattern of demyelination that did not follow the profile that is well 
characterized in C57BL/6 mice.  SJL mice did not readily demyelinate at the midline within 
the corpus callosum but showed greater demyelination immediately lateral to midline.  
During continuous exposure to cuprizone, demyelination was not complete and appeared to 
plateau after week 7.  Importantly, female mice were partially resistant to demyelination, 
while male mice were more severely demyelinated.  Differences in the number of mature 
oligodendrocytes were consistent with the extent of demyelination; however, microglia, 
astrocyte and oligodendrocyte precursor cell populations did not differ between male and 
female mice.  Thus, genetic factors and gender influence susceptibility to demyelinating 
disease in the cuprizone model, which may provide additional insights into the variability 





Multiple sclerosis (MS) is a degenerative disease of the central nervous system (CNS) 
in which autoimmune damage to myelin is a primary pathological finding.  Each year ten 
thousand individuals in the United States are diagnosed with MS, with women outnumbering 
men by at least two-fold.   In addition to gender differences in susceptibility, MS may also 
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display subtle differences in disease severity between men and women.  For instance, MRI 
scans of 281 female and 132 male MS patients showed that men had a lower number of 
contrast-enhancing lesions, which represent areas of active inflammation, but a higher 
number of “black hole” lesions, which mark axonal loss [14].  This suggests that men with 
MS may develop less inflammatory, but more destructive lesions.  Possible explanations for 
these gender differences include effects of gonadal hormones, inherent differences between 
male and female immune systems, or genetic factors that may or may not involve sex 
chromosomes.  
In the experimental autoimmune encephalomyelitis (EAE) animal model for 
demyelinating disease, several strains of rodents display gender differences in disease 
incidence and severity ([46], [63] [64] [42]).  However, the nature of the gender difference is 
highly dependent upon specific strain characteristics and the method of disease induction.  A 
comprehensive comparison of EAE clinical disease scores in several mouse strains revealed 
that female SJL and ASW have more severe EAE than males when induced by active 
immunization [46].  In addition, female NZW show a higher incidence of EAE than males, 
but male B10.PL and PL/J have more severe EAE than females.  There was no appreciable 
sex difference in active EAE in C57BL/6 or NOD mice.  This indicates that genetic 
variability has a strong influence on gender differences in EAE.   The influence of gender has 
also been explored in Theiler’s murine encephalomyelitis virus (TMEV)-induced 
demyelinating disease in mice.  In this model, male SJL/J display more severe neurological 
deficits than female mice [69].  The fact that SJL mice show gender differences in both the 
EAE and TMEV models indicates that the SJL strain is a logical choice for gender studies in 
the cuprizone model.  
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Early studies characterizing CNS pathology resulting from cuprizone treatment in 
ICI, Swiss and Swiss-Webster mice used large doses of cuprizone, in the 0.5-0.6% range, to 
induce demyelination [146, 151, 152].  In these early cuprizone studies male mice were used, 
and it was noted that female Swiss mice were not susceptible to cuprizone-induced 
demyelination [146].  In contrast, Elsworth and Howell cited using equal ratios of male and 
female albino mice for their studies, but did not note whether any gender differences were 
observed [158]. These studies focused on characterization of demyelination, oligodendrocyte 
depletion and the numbers of microglia and astrocytes in the cerebellar peduncles using 
electron microscopy [146].  Demyelination appeared complete by the fifth week of treatment. 
In each strain, differences in cuprizone dosage, time course of demyelination and cellular 
changes were noted with a high degree of accuracy.  In addition, staining for MBP and MAG 
by immunohistochemistry showed changes that correlated with demyelination and 
remyelination in the superior cerebellar peduncle [177].  However, several limitations, 
including the genetic background prevented full utility of the model. 
In the C57BL/6 strain, initial studies indicated that a lower dose of 0.2% of cuprizone 
was optimal [161] to induce full demyelination of the midline corpus callosum at week 5.  
Coincident with mature oligodendrocyte apoptosis, demyelination was accompanied by 
accumulation of microglia and astrocytes within the developing lesion.  Interestingly, this 
environment appears to promote infiltration of oligodendrocyte precursor cells (OPCs) 
presumably from the subventricular zone [148, 162].  When cuprizone is removed from the 
diet, OPCs differentiate into mature oligodendrocytes and remyelination occurs over the next 
5-7 weeks.  Thus, acute exposure to cuprizone results in a consistent temporal pattern of 
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demyelination and remyelination that is marked by specific cellular, biochemical and 
molecular changes. 
In contrast, the continuous exposure of C57BL/6 mice to cuprizone results in a 
pattern of two cycles of demyelination and remyelination, followed by chronic demyelination 
from which animals do not recover [148, 166].  The first remyelination is robust but 
incomplete and the second remyelination is limited [148].  In this strain, the inability to 
remyelinate is associated with a depletion of OPCs and can be stimulated by injection of 
functional OPCs into the lesion [178]. Thus, the C57BL/6 cuprizone model has been useful 
to our understanding of the limitations to repair that occur in chronically demyelinated 
lesions in multiple sclerosis [179, 180]. 
Our initial studies of the role of gender in C57BL/6 mice in the cuprizone model 
(soon to be published), and the lack of sex differences in EAE in C57BL/6 mice indicate that 
this strain may not be a good choice for the study of gender factors in the cuprizone model.  
Here the focus is on SJL mice, with the goal of determining whether gender influences the 
pattern of demyelination and remyelination in cuprizone toxicity.  The data indicate that SJL 
mice show a different temporal and spatial pattern of cuprizone-induced demyelination than 
C57BL/6 mice.  In addition, unlike C57BL/6 mice, female SJL mice show less severe 







2.3 MATERIALS AND METHODS 
 
Animals and cuprizone treatment:   
Adult male and female SJL/J mice were purchased from Jackson Laboratories (Bar Harbor, 
ME) and used for experiments at 8 weeks of age.  An initial dose titration was performed 
with 0.1%, 0.2%, 0.3%, 0.4% and 0.5%  cuprizone (oxalic bis(cyclohexylidenehydrazide)) 
(Sigma-Aldrich) mixed into ground or Purina mouse chow and fed ad libitum for 5 weeks. In 
order to determine the temporal pattern of cuprizone induced demyelination, both male and 
female mice were either untreated, or treated with 0.2% cuprizone (as was determined to be 
the optimal dose) for 3, 4, 5, 6, 7, 8, 9, or 10 weeks. The data for this time course is presented 
as a combination of two separate experiments, each of which included 4 male and 4 female 
mice at each time point, for a total of 8 animals of each gender at each time point. Untreated 
mice were fed ground Purina chow during the time that experimental mice were being treated 
with cuprizone. A preliminary study of remyelination during the second time course was 
performed with 4 male and 4 female mice, which were treated with 0.2% cuprizone for 7 
weeks then switched to a normal diet for 3 weeks. Also, 4 additional mice of each gender 
were treated with 0.2% cuprizone for 3, 6, or 8 weeks in order to assess oligodendrocyte 
progenitor cells, which require frozen sections. In addition, 4 male C57BL/6J mice bred in a 
pathogen-free facility at University of North Carolina-Chapel Hill (UNC-CH), were treated 
with 0.2% cuprizone for 5 weeks along with the SJL mice as a control for the expected 
pattern of demyelination as previously described [148, 161].  A comparison of these mice 
with SJL is shown in Figure 2.1.  All animal breeding and use was performed in compliance 
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with the NIH Guide for Care and Use of Laboratory Animals and approved by the UNC-CH 
Institutional Animal Care and Use Committee.  
 
Tissue Preparation: For mice treated to look at oligodendrocyte precursor cells, brains were 
removed, submerged in freezing media and immediately frozen in a supercooled isopentane 
bath.  All other mice were deeply anesthetized and intracardially perfused with 0.15M 
phosphate buffer followed by 4% paraformaldehyde (PFA) solution. Brains were removed, 
post fixed overnight in PFA, and embedded in paraffin.  5µm coronal brain sections were cut 
at the fornix region of the corpus callosum (approximately Bregma -0.5mm to -0.7mm) and 
corresponding to Figure 37 of The Mouse Brain In Sterotaxic Coordinates [181].   
 
Luxol Fast Blue – Periodic Acid Schiff’s (LFB-PAS) stain: To examine demyelination and 
remyelination, paraffin sections were stained with Luxol fast blue (Sigma, St. Louis, MI), 
which stains myelin blue, and periodic acid-Schiff (Sigma, St. Louis, MI), which stains 
microglia/macrophages and demyelinated axons pink.  Sections were scored blinded based 
on the amount of blue or pink fibers in the corpus callosum, on a scale from 3 (complete 
myelination equal to an untreated mouse) to 0 (complete demyelination, as seen during peak 
cuprizone demyelination).  The regions analyzed were the midline corpus callosum, and a 
region just lateral to midline (illustrated in Figure 2.1).   
 
Immunohistochemistry: The detection of mature oligodendrocytes was performed with 
antibody to the Pi isoform of glutathione S-transferase (GST ) (Biotrin, Newton, MA).  
Paraffin sections were rehydrated and permeabilized with 0.1% Triton X-100/ 2% normal 
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goat serum in phosphate buffered saline (PBS) for 20 minutes at room temperature.  Tissue 
was unmasked in 0.1% calcium chloride/ 0.1% trypsin in 0.05M Tris, pH 7.4 for 15 minutes 
at 37oC.  Sections were rinsed in PBS and incubated with GSTpi antibody (1:1000) or isotype 
control overnight at 4oC.  Following appropriate rinsing, sections were incubated for 1 hour 
at room temp with a goat anti-rabbit IgG AlexaFluor  conjugated secondary antibody (1:400) 
(Molecular Probes, Eugene, OR), rinsed and cover slipped with Vectasheild plus DAPI 
(Vector Laboratories Inc, Burlingame, CA) to counter stain nuclei.   
Microglia/macrophages were detected with biotinylated lectin Ricinus communis 
agglutin-1 (RCA-1) (Vector Laboratories Inc, Burlingame, CA).  Paraffin sections were 
rehydrated and unmasked with 0.025% protease, type XIV (Sigma-Aldrich) for 2 minutes at 
43 oC. Following a brief rinse in PBS they were blocked with 0.1% Triton X-100/ 1% bovine 
serum albumin in PBS for 1 hour at room temperature.  Sections were then incubated with 
RCA-1, 1:500 in blocking solution or blocking solution alone as a control, overnight at 4oC.  
Following appropriate rinsing, sections were incubated for 1 hour at room temp with a 
streptavidin AlexaFluor conjugated secondary reagent (1:400) (Molecular Probes, Eugene, 
OR), rinsed and cover slipped with Vectasheild plus DAPI (Vector Laboratories Inc, 
Burlingame, CA) to counter stain nuclei. 
Astrocytes were detected with antibody to glial fibrillary acidic protein (GFAP) 
(Invitrogen). Paraffin sections were rehydrated and unmasked with 0.025% protease, type 
XIV (Sigma-Aldrich) for 2 minutes at 43 oC. Following a brief rinse in PBS they were 
blocked with 0.1% Triton X-100/ 2% normal goat serum in PBS for 1 hour at room 
temperature.  Sections were then incubated with GFAP antibody (1:200) or isotype control 
overnight at 4oC.  Following rinsing, sections were incubated for 1 hour at room temp with a 
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goat anti-rat IgG AlexaFluor conjugated secondary antibody (1:400) (Molecular Probes, 
Eugene, OR), rinsed and cover slipped with Vectasheild plus DAPI (Vector Laboratories Inc, 
Burlingame, CA) to counter stain nuclei. 
Oligodendrocyte precursor cells were detected with a rabbit antibody to NG2, a kind 
gift from Dr. W.B. Stallcup (BIMR, La Jolla, CA).  Five micrometer frozen sections were 
fixed in 95% ethanol before being stored at -80 oC.  Upon removal from the freezer, sections 
were post-fixed in cold acetone, rinsed in KPBS, and blocked with 0.1% Triton X-100/ 5% 
normal goat serum in KPBS for 1 hour at room temperature.  Sections were then incubated 
with NG2 antibody (1:500 in blocking solution) or isotype control overnight at 4oC.  
Following rinsing, sections were incubated for 1 hour at room temp with a goat anti-rabbit 
IgG AlexaFluor-conjugated secondary antibody (1:600) (Molecular Probes, Eugene, OR), 
rinsed and cover slipped with Vectashield plus DAPI (Vector Laboratories Inc, Burlingame, 
CA) to counter stain nuclei. 
All comparative analyses were focused in the corpus callosum at the midline or just 
lateral to midline (Figure 2.1). Immunohistochemically positive cells were analyzed using a 
Nikon (Tokyo, Japan) Optiphot FXA microscope with epifluorescence optics and quantified 
per square mm. Positive-stained cells were counted only if a nucleus was observed.  
 
Statistical analysis: Statistical comparisons between time points for each gender separately 
were carried out using a one-factor ANOVA and Tukey’s test for multiple comparisons.  
Statistical analysis to determine whether there was a gender effect was made using a two-
factor ANOVA and Bonferroni correction for comparisons between time points. The data are 




Localization of Demyelination within the Corpus Callosum of SJL mice. 
We first examined brains of SJL mice for demyelination at 5 weeks following 
exposure to cuprizone, the time when demyelination is complete in the C57BL/6 mouse [148, 
161, 164]. Coronal sections were stained with LFB-PAS to determine the extent of 
demyelination.  Robust demyelination did not occur at midline as observed in C57BL/6 mice, 
but instead, localized immediately lateral to midline (Figure 2.1).  In addition, there appears 
to be two different layers of myelinated fibers, each showing distinct patterns of 
demyelination, with the lower lateral layer, adjacent to the fornix, showing less 
demyelination than the upper lateral layer (Figure 2.1B). Myelination scores reflect a 
combination of both of these layers.  This pattern is more similar to that occurring in the 
caudal corpus callosum in the C57BL/6 mice at the level of the hippocampus, in which three 
myelin layers are sometimes observed (unpublished observations).  Although the lateral areas 
appear to be more susceptible to demyelination than the midline in SJL mice, we have 





Figure 2.1. Illustration of areas scored for myelination in SJL and C57BL6 corpus callosum.   
A. Midline scores were derived from coronal sections of the SJL brain above the fornix 
(Bregma -0.5 to -0.7) as indicated by the solid box in the left figure.  Lateral scores were 
immediately adjacent to the midline areas of the corpus callosum that is depicted by the solid 
box in the right figure.  Far lateral areas indicated by the dotted box also showed 
demyelination but were not scored.  The letter “V” indicates a ventricle.  
B. Comparison of demyelination in midline versus lateral corpus callosum of SJL and 
C57BL/6 mice.  LFB-PAS stain for myelin (blue fibers), microglia/macrophages (pink 
cytoplasm) and demyelinated axons (pink fibers).  Left column depicts the regions that were 
scored for demyelination: midline and lateral, scale bars represent 200 µM length.  In the 
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right two columns, the corpus callosum is outlined by dotted lines and shows representative 
images of  lateral and midline regions from untreated, 5 week and 10 week cuprizone treated 
animals. Right two column scale bars represent 50 micrometer length.  Note the presence of 
two layers of fiber tracts in SJL, especially evident in the 10 week treated brain.  The bottom 
row shows midline and lateral areas of 5 week treated C57BL/6 mice that were treated along 
side the SJL mice and are typical of the robust demyelination and gliosis previously reported 
in this strain. 
 
 
Titration of cuprizone in SJL mice 
 SJL mice were exposed to different concentrations of cuprizone (0.1, 0.2, 0.3, 0.4, 
0.5%) in the diet to determine the amount of cuprizone required to induce demyelination 
without significant toxicity.  Again, mice were sacrificed at week 5, corresponding to the 
time of full demyelination in C57BL/6 mice.  Mice on a diet of 0.3% or greater exhibited 
overt toxic effects of cuprizone indicated by diminished weight, lethargy and lack of 
grooming.  Over half of the animals from these groups succumbed to the higher doses, 
similar to C57BL/6 mice. 0.1% cuprizone induced very little demyelination, not significantly 
different from untreated. Therefore, we determined that 0.2% provided the optimal cuprizone 
dosage to administer to SJL mice.  
 
Temporal pattern of demyelination at midline and lateral areas of the corpus callosum. 
 
Male and female SJL mice were treated continuously with 0.2% cuprizone for 3 to 10 
weeks and analyzed at weekly intervals to determine the time frame of maximal 
demyelination and possible remyelinating episodes.  Sections of the corpus callosum were 
stained for myelin with LFB-PAS and scored in a blinded manner both at midline and lateral 
regions.  Demyelination was also observed far lateral in the corpus callosum, on the opposite 
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side of the ventricle (Figure 2.1A),  However, the fiber density and variability made scoring 
less reliable in these regions, so they were not included in the illustrated assessments.   As 
shown in Figure 2, demyelination in male and female mice continuously exposed to 
cuprizone occurred gradually, from week 3 to week 10.  In the midline region (Figure 2.2A) 
cuprizone-treated male SJL mice showed significantly greater demyelination at weeks 8-10 
compared with untreated mice (p<0.05; one factor ANOVA with Tukey’s post-test).   In 
female SJL mice in the midline region, demyelination reached a statistically significant 
difference from untreated mice only at weeks 9 and 10 (p<0.001).  Comparison of male and 
female mice using two-factor ANOVA showed a significant gender effect on demyelination 
over the entire observed time period (p=0.0010).  The midline corpus callosum showed only 
partial demyelination and remyelination was not observed during the course of cuprizone 
administration.   
 The same coronal sections of brains from SJL mice continuously exposed to 
cuprizone were scored for demyelination immediately lateral to the midline area (See Figure 
2.1).  As shown in Figure 2.2B, the temporal pattern of demyelination in the lateral areas is 
dramatically different than at midline.  Mild demyelination was detected in male SJL mice 
beginning at week 3, reaching statistical significance compared with untreated mice at weeks 
5 and 6 (p<0.05).  More robust demyelination was observed in males at week 7 (p<0.001), 
reaching a plateau through week 10.  The partial demyelination present at week 10 persists as 
long as week 13 (data not shown).  Thus, unlike male C57BL/6 mice, which show three 
cycles of demyelination while on continuous exposure to cuprizone over 13 weeks [166], SJL 
mice appear to demyelinate gradually once during these time points; however, the 
demyelination is incomplete. 
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Equally important in female SJL mice, demyelination showed a slow, delayed course 
of demyelination (Figure 2.2B), which is moderate from weeks 3 through 6 and does not 
reach a statistically significant difference from untreated until week 7 (p< 0.001).  This is in 
contrast to males which reached statistically significant demyelination by week 5. From 
weeks 5 to 10, female SJL mice exhibit less demyelination than male counterparts, and this 
gender effect over the entire observed time period is significant (two factor ANOVA 
p=0.0305).  Thus, female SJL mice appear to be less susceptible to demyelination than male 
mice.  In both male and female SJL there is no apparent remyelination during this time 
period. 
 A preliminary study of remyelination was performed by removing cuprizone from 
the diet at the 7 week time point, and allowing the mice to recover for 3 weeks.  Interestingly, 
when compared to the 7 week time point, significant remyelination had not occurred in either 
the midline or lateral regions (Figure 2.2A and 2.2B).  Furthermore, there was no significant 







Figure 2.2.  Cuprizone-induced demyelination of the SJL corpus callosum.   
Myelination scores of the corpus callosum from male and female SJL mice continuously 
exposed to cuprizone (8 mice per gender per group, except the recovery time point which is 
composed of 4 mice per gender per group).  
A. Midline corpus callosum: two-factor ANOVA indicates a significant gender effect 
(p=0.0010).  B. Lateral corpus callosum: two-factor ANOVA indicates a significant gender 
effect p=0.0305.   C. Representative images of LFB-PAS stain in male (M) and female (F) 
lateral corpus callosum at selected time points.  Scale bar equals 50 µM 
 
  
Quantification of mature oligodendrocytes. 
In C57BL/6 mice continuously exposed to cuprizone, mature oligodendrocytes are 
depleted by week 5 and recover temporarily at week 6 before diminishing a second time 
[178].  Here, we quantified the mature oligodendrocyte population in the midline and lateral 
areas.  Untreated male and female mice begin with similar numbers of oligodendrocytes in 
the corpus callosum (Figure 2.3). As shown in Figure 2.3A, the number of mature 
oligodendrocytes at midline is initially diminished at week 3 but did not reach a statistically 
significant difference from untreated mice until week 5.  Thereafter the number of mature 
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oligodendrocytes appears to plateau through week 10.  Except for week 7, female mice show 
a trend for greater numbers of mature oligodendrocytes than male mice from week 3-10, 
particularly at week 8. The overall gender effect by two-factor ANOVA is statistically 
significant (p=0.0158).  Thus, similar to demyelination in Figure 2.2, there are significantly 
more mature oligodendrocytes in female mice than male mice. 
In the lateral regions of the corpus callosum, a gradual depletion of mature 
oligodendrocytes is observed in both male and female mice, beginning at week 3, compared 
with untreated mice (p<0.01; Figure 2.3B).  Female mice have more oligodendrocytes than 
male counterparts at all time points, and this gender effect is highly significant (p<.0001).  
Interestingly at weeks 8 and 9, there is a trend for recovery of mature oligodendrocytes in 
both males and females.  By week 10, the number of mature oligodendrocytes again 
diminishes.  However, similar to demyelination, full depletion of mature oligodendrocytes is 
not observed during this time period. 
When cuprizone administration was discontinued at week 7 and mice were allowed to 
recover for 3 weeks, a modest increase in oligodendrocytes was observed at both midline and 
lateral regions; however,  statistical significance was observed only in the lateral region 
(Figure 2.3B, p<0.05 for both male and females).  However, there is no gender difference in 
the number of oligodendrocytes during this recovery time point (7+3 week).  This increase in 
oligodendrocytes indicates that SJL mice are capable of recovery from cuprizone-induced 








Figure 2.3.  Mature oligodendrocytes in the corpus callosum of SJL mice.   
Male and female mice were treated with cuprizone continuously over the time course 
indicated (8 mice per gender per group, except the recovery time point which is composed of 
4 mice per gender per group).   
A. Numbers of GSTpi+ oligodendrocytes were quantified from the midline of the corpus 
callosum. Two-factor ANOVA indicates a significant gender effect p=0.0158.   
B. Numbers of GSTpi+ oligodendrocytes were quantified from lateral areas of the corpus 
callosum. Two-factor ANOVA indicates a significant gender effect p<0.0001.   
C. Representative images of mature oligodendrocytes identified by immunoreactivity to 
GSTpi in male (M) and female (F) lateral corpus callosum at selected time points.  Scale bar 











Oligodendrocyte precursor cells accumulate in the demyelinated lesion. 
 The accumulation of oligodendrocyte precursor cells (OPCs) in demyelinated lesions 
has been noted since the earliest cuprizone studies in both ICI and Swiss mice [146, 152].  In 
these studies OPCs were identified by ultrastructural characteristics and were detected at 5 
weeks of cuprizone treatment when the lesions in superior cerebellar peduncles were nearly 
fully demyelinated.  The availability of antibodies to the NG2 protein, which is commonly 
used as one marker for OPCs, has allowed for easier quantification of these cells.  In 
C57BL/6 mice, NG2-positive OPCs are present in limited numbers in untreated mice, 
accumulate during cuprizone-induced demyelination and reach maximal numbers at 4 and 5 
weeks of intoxication [162].  During recovery, OPC numbers decline slightly, presumably 
due to their maturation into oligodendrocytes that are responsible for the remyelination of the 
lesion [162, 165].  However, chronic administration of cuprizone (8-12 weeks), leads to 
progressive depletion of OPCs from the lesion [178]  Here, we used the NG2 marker to 
identify the pattern of OPC accumulation in SJL male and female mice at select times during 
demyelination.  A quantification of NG2-positive OPCs indicates that a few of these cells are 
present in the untreated corpus callosum, in similar numbers between male and female SJL 
(Figure 2.4).  During cuprizone intoxication, OPC numbers increase gradually, becoming 
statistically significant at the 8 week time point.  Unlike the response of mature 
oligodendrocytes, the numbers of OPCs are very similar in the midline and lateral regions of 
the corpus callosum.  In addition, OPCs seem to differ from mature oligodendrocytes in that 







Figure 2.4.  Oligodendrocyte precursor cells (OPCs) in the corpus callosum of SJL mice.   
Male and female mice were treated with cuprizone continuously over the time course 
indicated (4 mice per gender per group).   
A. Numbers of NG2+ OPCs were quantified from the midline of the corpus callosum. Two-
factor ANOVA indicates there is no significant gender effect.   
B. Numbers of NG2+ OPCs were quantified from the lateral corpus callosum. Two-factor 
ANOVA indicates there is no significant gender effect.   
C. Representative images of OPCs identified by immunoreactivity to NG2 in male (M) and 









Quantification of microglia 
 Microglia appear during demyelination and typically disappear with remyelination 
[165, 178, 182].  Here we assessed the microglial response at midline and lateral regions to 
determine if their numbers correlated with the extent of demyelination.  As show in Figure 
2.5A, microglia accumulation at midline in both male and female mice is detected at weeks 3 
and 5 and becomes statistically significant compared to untreated during weeks 6 through 10 
(p<0.05). In female mice there appears to be a plateau from week 6 through week 10, 
whereas male mice exhibit an upward trend in microglial numbers through week 9. At a few 
time points microglia accumulation appears to be less robust in female mice; however, there 
is not a statistically significant gender effect.   
 In the lateral regions, female and male mice show microglia accumulating between 
week 3 through week 6 and then the number of microglia appear to level off (Figure 2.5B).  
There are no significant differences among male and female mice in terms of microglial 
responses to demyelination.  Interestingly, the number of microglia in the lateral regions is 
greater in number compared to the midline, probably due to the greater demyelination 








Figure 2.5.  Microglia in the corpus callosum of SJL mice.   
Male and female mice were treated with cuprizone continuously over the time course 
indicated (8 mice per gender per group).   
A. Numbers of RCA-1+ microglia were quantified from the midline of the corpus callosum. 
Two-factor ANOVA indicates there is no significant gender effect.   
B. Numbers of RCA-1+ microglia/macrophages were quantified from the lateral corpus 
callosum. Two-factor ANOVA indicates there is no significant gender effect.   
C. Representative images of microglia/macrophages identified by reactivity to the lectin 
RCA-1 in male (M) and female (F) lateral corpus callosum at selected time points.  Scale bar 











Quantification of astrocytes 
 Similar to microglia (though fewer in number), astrocytes infiltrate the demyelinated 
lesion, but unlike microglia, typically persist through remyelination [182].  Here we assessed 
whether differences observed for demyelination and mature oligodendrocyte scores could be 
partly explained by the astrocyte populations.  At midline, an endogenous population is 
present as expected and there is no difference between male and female mice.  After 
exposure to cuprizone, a higher number of astrocytes begin to populate the midline of the 
corpus callosum and by week 5, they appear to have reached maximal numbers in both male 
and female mice (Figure 2.6A).  There is no difference in the astrocyte response between 
male and female mice at midline. 
 In the lateral areas, the appearance of astrocytes is very similar to the midline scores.  
Interestingly, unlike the greater number of microglia found in the lateral areas, astrocyte 
numbers (~500 cells/mm2) in the lateral regions are similar to the numbers at midline.  
Although female mice appear to have a slight trend for higher numbers of astrocytes at 







Figure 2.6.  Astrocytes in the corpus callosum of SJL mice.   
Male and female mice were treated with cuprizone continuously over the time course 
indicated (8 mice per gender per group).   
A. Numbers of GFAP+ astrocytes were quantified from the midline of the corpus callosum. 
Two-factor ANOVA indicates there is no significant gender effect.   
B. Numbers of GFAP+ astrocytes were quantified from the lateral corpus callosum. Two-
factor ANOVA indicates there is no significant gender effect   
C. Representative images of astrocytes identified by immunoreactivity to GFAP in male (M) 






 The SJL strain of mice revealed several differences when compared to C57BL/6 mice 
in the cuprizone model of demyelination.  First, the location of appreciable demyelination 
within the corpus callosum is immediately lateral to midline, rather than midline, as observed 
in the C57BL/6 mouse.  Second, demyelination is only partial in SJL mice through 10 weeks 
of continuous treatment whereas full demyelination is observed at week 5 in C57BL/6.  
Third, demyelination was less severe in female SJL mice than male mice.  Fourth, mature 
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oligodendrocytes in female SJL mice were more resistant to depletion than male 
counterparts.  There were no apparent differences between the sexes in the number of 
oligodendrocyte precursors, microglia or astrocytes in the demyelinated regions.  
Furthermore, unlike C57BL/6 mice which remyelinate quickly upon discontinuation of 
cuprizone, SJL mice which were treated with cuprizone for 7 weeks and then allowed to 
recover for 3 weeks showed only slight remyelination. However, SJL mice are similar to 
C57BL/6 mice in that a 0.2% diet of cuprizone promotes demyelination without the severe 
toxic effects observed at 0.3% diet of cuprizone or greater. 
Interestingly, several strains of mice show differences in sensitivity to cuprizone 
intoxication.  Studies of ICI and Swiss Webster mice used 0.5% to 0.6% cuprizone in their 
diet to induce demyelination [146, 183, 184].  Though not tolerated by all of these mice, 
many of them mice lived for months on the cuprizone diet.  In contrast, C57BL/6 mice and 
SJL mice are more susceptible to cuprizone, showing demyelination at the lower 0.2% dose.  
Similar to C57BL/6 mice [161], SJL mice die or are lethargic at 0.3%, and higher doses of 
0.4, 0.5 and 0.6% resulted in death within the first couple of weeks.  It is not clear why there 
is strain variability in sensitivity to cuprizone.  Recently, strain differences have been 
reported for cortical demyelination induced by cuprizone.  In this study BALB/cJ mice were 
treated with 0.2% cuprizone and compared to C57BL/6 [160].  The BALB/cJ mice were 
reported to have a similar pattern of demyelination in the corpus callosum, but less 
demyelination and more microglia activation in the cortex as compared to C57BL/6. 
The difference in response due to genetic background becomes important also when 
crosses of different mice are used to analyze specific genes.  Unless there is an attempt to 
backcross to an established genotype such as C57BL/6, the background genes of the 
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knockout or transgenic mice are not homogeneous and could influence outcomes.  This may 
be also true for 129 mice which have similar patterns of demyelination in the corpus 
callosum as C57BL/6, but demyelinate at a lower dose of 0.1% of cuprizone (data not 
shown).  Thus, mice on the 129 background may show more severe effects if tested at the 
0.2% cuprizone dose and mice of a mixed background may give a more complicated pattern. 
The data in this manuscript emphasize the importance of considering the influence of genetic 
background in the study of demyelination, regardless of the model, (EAE, viral or toxin-
induced demyelination).   
Genetic background clearly influences the morphologic and temporal pattern of 
demyelination.  We found SJL mice demyelinate partially at midline (Figure 2.2A), while 
C57BL/6 mice show robust demyelination, particularly at week 5 [161, 164, 165].  SJL mice 
show greater demyelination in the lateral region of the corpus callosum immediately adjacent 
to the midline; however, two distinct layers appeared to demyelinate differently.  The lower 
one third is more resistant to demyelination than the upper two thirds (Figure 2.1B), hence, 
myelin scores in the SJL mice are a bit more complex requiring a cumulative subjective 
combination.  Scores in Figure 2.2B are reflective of the entire lateral corpus callosum region 
indicated in Figure 2.1.  The utility of the LFB-PAS histological stain is illustrated here as 
myelin fibers that are stained blue versus unmyelinated fibers that stain pink can be estimated 
quickly for a large number of samples.  It would be cumbersome to assess these sections by 
electron micrography since all axons within the tract would have to be counted because 
representative areas would be difficult to choose. Previous studies have shown that LFB-PAS 
scores are reflective to trends in demyelination when compared to percent myelinated fibers 
that are counted in electron micrographs [166, 185]. However, one limitation of the LFB-
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PAS stain is that one cannot detect whether any remyelination is occurring during the 
demyelination period.  In order to determine whether there is any remyelination occurring 
during the cuprizone treatment, electron microscopy could be employed to monitor thinly 
myelinated axons which are characteristic of remyelination [186].  However, in C57BL/6 
mice, we do not detect any apparent remyelination in the midst of demyelination and 
remyelinated axons are not detected until after complete demyelination which occurs at week 
5. 
The reason for regional differences in demyelination of the corpus callosum observed 
in SJL mice is not known.  There are many examples of regional differences in 
dysmyelination due to genetic manipulation of mice between areas such as the optic nerve, 
spinal cord, cerebellum, and corpus callosum.  For example, laminin deficient 
dystrophia muscularis (dy/dy) mice exhibit hypomyelination in the corpus callosum and optic 
nerve, but not the spinal cord [187] whereas dominant negative β1 integrin ∆C mice are 
hypomyelinated in spinal cord and optic nerve, but not the corpus callosum [188].  
Heterogeneity of oligodendrocytes is one possible explanation for such regional differences, 
however this seems unlikely in the present case, given that we are seeing differences within 
the corpus callosum rather than between different white matter regions.   One possible 
explanation for the appearance of two different layers of demyelination (Figure 2.1B) in the 
lateral region of SJL corpus callosum during demyelination is that these may represent two 
different groups of axonal fibers coming from different types of neurons and are providing 
different levels of trophic support or conversely different levels of detrimental signaling.  
Similar layers that show differential demyelination in C57BL/6 mice occur in a more caudal 
regions of the corpus callosum next to the hippocampus (data not shown) and the reasons for 
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these differences is not clear.  Another alternative explanation is that the cuprizone has better 
access to oligodendrocytes in the upper lateral layers or these oligodendrocytes are 
hypersensitive to insult.   
 Our temporal analysis of demyelination in the lateral corpus callosum indicates 7 
weeks of cuprizone treatment is optimal for detecting marked demyelination in SJL mice.  
From 7 weeks on, there is only modest continued demyelination. In addition, 7 weeks is 
when the greatest loss of oligodendrocytes was observed in both genders.  One of the more 
striking differences in SJL mice is the lack of total demyelination during a 10 week period of 
continuous exposure to cuprizone.  This is very different than C57BL/6 mice which fully 
demyelinate by week 5.  Even out to week 13 of continuous exposure to cuprizone, 
demyelination scores were approximately 0.75 for males and 1.0 for females at the lateral 
region, similar to week 10 scores in Figure 2.2B.  Although higher doses may induce full 
demyelination, we could not examine SJL mice at doses of 0.3% or greater as they are 
susceptible to systemic toxicity. In addition, C57BL/6 mice experience a spontaneous partial 
remyelination after 6 weeks and then continue to demyelinate further when exposed 
continuously to cuprizone [148, 166]. Despite a trend for an increase in the oligodendrocyte 
population at weeks 8 and 9, we did not detect any remyelination during continuous 
cuprizone exposure in SJL mice.   
An additional interesting difference of SJL mice from C57BL/6 mice, is the lack of 
robust remyelination after 3 weeks of recovery from the cuprizone diet.  C57BL/6 mice show 
greater than 50% remyelination within 2 weeks of discontinuation of cuprizone [163, 165], 
which is in stark contrast to the reduced remyelination report here for SJL.  However, it 
should be emphasized that the remyelination analysis performed here is limited and a more 
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thorough examination to determine whether remyelination progresses further would require 
later time points.  The quantification of mature oligodendrocytes indicates that there is some 
recovery of these cells after 3 weeks of removal from cuprizone, and it is possible that this 
would lead to greater remyelination at later time points.  A less robust remyelination in SJL 
could be explained by the less robust infiltration of microglia and astrocytes which are 
known to produce factors such as IGF-1 and TNFα that are important for promoting 
remyelination [164, 165, 189]. 
Another important finding is the difference between male and female SJL mice 
during demyelination.  At many time points, male mice were more severely demyelinated 
than female mice in both midline and lateral regions, and the overall gender effect was 
statistically significant.  In addition, when we analyzed the oligodendrocyte populations at 
midline and lateral regions, we found a statistically significant preservation of 
oligodendrocytes in female mice compared to males (Figure 2.3). Thus, female SJL mice are 
more resistant to oligodendrocyte loss and demyelination, and this trend was observed at 
most of the time points between weeks 5 through 10.  A difference in the size of corpus 
callosum or numbers of oligodendrocytes in untreated mice is unlikely to explain the 
resistance to toxicity reported here.  As shown in Figure 2.3, untreated male and female SJL 
mice have similar numbers of oligodendrocytes in the corpus callosum.  Although, the size of 
the corpus callosum was not measured here, data published by Bishop and Walsten [190] 
indicate that unlike in humans or rats, mice do not display a gender difference in corpus 
callosum size. The lack of difference in numbers of OPCs (Figure 2.4) and remyelination 
(Figure 2.2) between male and female SJL suggest that there is no gender difference in 
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proliferation, migration, or maturation of oligodendrocytes.  Additional future experiments to 
further characterize remyelination in SJL mice may clarify this point.    
It is possible that female gender affords a protection from toxicity in general, which is 
supported by our observations during the cuprizone dose titration that male mice died more 
quickly when exposed to higher doses of cuprizone (data not shown).  Analysis of liver 
sections indicated that at the 0.2% cuprizone dose, there is little indication of toxicity in 
either gender as indicated by vacuolation or necrosis, but male mice do exhibit an increase in 
binucleated hepatocytes compared to untreated mice, whereas females do not (data not 
shown).  Whether this indicates that female mice may handle cuprizone differently than 
males, or whether mechanisms for protecting oligodendrocytes in female brains are superior 
to those in male mice remains to be determined.  A final note, Swiss female mice have been 
reported to be resistant to cuprizone-induced demyelination; however, the mechanism for 
such differences compared to male Swiss mice is not known [146].  Studies of dietary copper 
deficiency in rats indicate that females exhibit less severe symptoms of weight loss, anemia, 
and lethality [191-193].  The mechanism of this gender difference is not known and the 
potential role of endogenous sex hormones is controversial.  One study found an 
exacerbation of some copper deficient symptoms, such as weight loss, in ovariectomized 
females [194] but no effect on severity by male or female sex hormones was detected in 
another study [193].  It is possible that the protective effect from dietary copper deficiency or 
cuprizone-chelated copper deficiency may be similar in these female subjects; however, the 
inherent mechanism remains elusive. 
Nevertheless these findings of gender differences are in contrast to those in the EAE 
model, in which female SJL are both more susceptible to disease induction, and exhibit more 
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severe neurological deficits [42, 46, 63].  The fact that female SJL mice show increased 
severity in EAE, but decreased severity in cuprizone intoxication may reflect a key difference 
between EAE and cuprizone models: EAE has an autoimmune etiology, while cuprizone 
delivers a toxic injury to oligodendrocytes. The increased severity in EAE may be due to T 
cell immune mechanisms which are not induced by cuprizone intoxication [165],[168]. Thus, 
in spite of a low threshold for autoimmunity in SJL females, female SJL oligodendrocytes 
appear to exhibit a high threshold, or resistance, to toxic injury.  The utility of both models 
for the study of MS is supported by heterogeneity in MS lesions, reported by Lucchinetti and 
colleagues [6], in which type III and IV lesions suggest primary oligodendrocyte dystrophy, 
while type I and II lesions are consistent with T- or B-cell associated autoimmune 
mechanisms. Similar to our findings in the cuprizone model, female SJL mice infected with 
TMEV show less severe neurological deficits and a moderate (though not statistically 
significant) resistance to demyelination compared to males [69].   
Future studies to determine the mechanism of protection of female oligodendrocytes 
will be an important contribution to the growing body of work addressing the role of gender 
in neuropathological conditions.  There is much evidence for a role of sex hormones in 
demyelination and oligodendrocyte function.  In MS there is a clear protection from relapse 
during the third trimester of pregnancy when several hormones, especially sex steroids, reach 
a peak [78].  In EAE, administration of estrogens lead to functional benefits [66, 86, 89, 195].  
In addition, sex hormones have been shown to have direct effects on oligodendrocyte 
proliferation and maturation [131, 196] as well as survival [133, 134].  Cuprizone 
intoxication of SJL mice will be a useful model to study the role of sex hormones in primary 
oligodendrocyte disruption. 
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 We also monitored the microglia and astrocyte populations in the male and female 
mice.  In the midline corpus callosum microglia accumulation began by week 3 and reached 
statistically significant numbers compared with untreated mice by week 6, then remained 
unchanged through week 10, in both male and female mice. In the lateral regions, the 
microglial response was more robust, with nearly 30% more microglia/mm2 than at midline, 
and there was a slight decrease at week 10.  Overall there was not a difference between male 
and female mice.  Lastly, when we measured the astrocytic response both at midline and in 
the lateral regions, we observed an increase in astrocytes until week 5, when they stabilized 
in number.  Unlike microglia, astrocytes numbers in the lateral regions remained similar to 
numbers at midline and they did not increase appreciably.  Thus, unlike microglia and 
astrocytes in C57BL/6 mice that respond vigorously to demyelination [148, 161, 165], these 
cell types in SJL mice have a guarded response at midline and in the lateral region, which 
correlates with subdued demyelination.  There was no difference in microglia or astrocyte 
numbers between male and female SJL mice.  This study did not address specific functions 
of microglia or astrocytes, which may also be influenced by sex hormones [29, 136, 140, 
197-199] .  Future studies to address differences in cytokine and growth factor production 
that may provide protection for oligodendrocytes are warranted and would shed important 
light on the role of these cells in demyelinating disease.  
In conclusion, male and female SJL mice did not fully demyelinate during a period of 
10 weeks of continuous cuprizone exposure, when C57BL/6 mice would have undergone two 
rounds of full demyelination, indicating a clear genetic influence on susceptibility to 
demyelination.  Importantly, SJL female mice are more resistant than males to loss of 
oligodendrocytes and demyelination, though there were no gender differences in microglial 
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or astrocytic accumulation.  Further study of gender and hormonal influences in SJL mice 
using the cuprizone model will be an important complement to EAE studies given the 
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3.1 ABSTRACT 
 Demyelinating diseases such as multiple sclerosis may be influenced by gender 
dimorphisms.  Cuprizone-induced demyelination and remyelination have been extensively 
characterized in male mice, but a direct comparison with female mice has not been 
conducted.  We have undertaken a comprehensive characterization of the morphological and 
cellular processes that occur in female C57BL/6J mice during cuprizone-induced 
demyelination and subsequent remyelination, and compared this to age-matched male 
counterparts.  We find that the pattern of demyelination and remyelination is similar between 
genders, and that there is little to no difference in the loss or repopulation of mature 
oligodendrocytes, or accumulation of reactive glia. Interestingly, we found that cuprizone 
treatment disrupts estrous cyclicity in female mice, possibly interfering with potential 
hormone influences on demyelination and remyelination.  Therefore, cuprizone- induced 






Destruction of the myelin sheath and subsequent neurological impairments are 
hallmark characteristics of the degenerative disease multiple sclerosis (MS).  MS is thought 
to be an autoimmune disease, due to the presence of myelin reactive T cells present in 
demyelinated lesions.  Women are 2-3 times more likely to develop MS, a trend that is 
shared with many autoimmune diseases.  Gender may also have subtle effects on disease 
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severity, illustrated by a natural history study of greater than 1800 patients in which female 
gender  showed an association with slower progression of disease [13].  Also, MRI scans of 
281 female and 132 male MS patients revealed that men had a higher number of “black hole” 
lesions, which mark axonal loss [14].  A role for high levels of sex hormones is demonstrated 
by the finding that females have fewer relapses during pregnancy, when several sex 
hormones are elevated [78]. Given these gender dimorphisms in MS, it is critical to 
understand the mechanisms of sex differences in demyelinating disease.   
 The most frequently used animal model for MS is experimental autoimmune 
encephalomyelitis (EAE).  Sex differences occur in this model, and these vary by animal 
strain, suggesting a genetic influence.  Female SJL mice, commonly used in EAE studies, 
show a greater incidence and severity of disease, and are more likely to exhibit relapses than 
males [42, 46, 63-65]. However, other strains exhibit increased severity in males (B10.PL 
and PL/J) or no sex differences (NOD/lt and C57BL/6) [46]. Another autoimmune model of 
MS, intracerebral inoculation with Theiler’s murine encephalomyelitis virus (TMEV) also 
displays sex differences that vary by strain. Male C57L/J mice are more susceptible than 
females to TMEV-induced demyelinating disease [200], and male SJL mice exhibit more 
severe neurological deficits than females [69].    
 Models that involve chemically induced death of oligodendrocytes and demyelination 
are useful for the study of primary oligodendrocyte perturbation, which is hypothesized to 
occur as a component of the pathology in type 3 and 4 MS lesions [6].  These models are also 
very useful in the study of remyelination and recovery from oligodendrocyte loss.   Using the 
ethidium bromide toxin model, it was shown that young male and female rats display a 
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similar rate of remyelination, but in older rodents where remyelination occurs more slowly 
[201, 202], females remyelinated more efficiently than male counterparts [73]. 
Another toxin model that produces a well-defined and highly reproducible pattern of 
demyelination and remyelination is the cuprizone model.  Cuprizone is a copper chelator that 
has been used to induce demyelination in several strains of mice.  More recently, this model 
has been well characterized in male C57BL/6 mice.  Exposure to a low dose of cuprizone 
induces death of oligodendrocytes and loss of myelin in the corpus callosum fiber tract [161, 
162] as well as some degeneration and axonal loss, especially in older mice [174]. In the 
demyelinated lesion, oligodendrocyte loss is accompanied by active gliosis and accumulation 
of oligodendrocyte precursors [162].  Upon discontinuation of cuprizone treatment, full 
remyelination is achieved (reviewed in [148]). Although most earlier studies used male mice, 
partly because it was thought that female mice do not demyelinate [146], demyelination in 
female mice has been noted [148].  As more investigators are beginning to use female mice 
in cuprizone studies [170-175], it is important to have a similar knowledge base of the 
processes occurring in female mice during cuprizone treatment.  Furthermore, to our 
knowledge, no direct comparisons between male and female C57BL/6 mice have been made 
in the cuprizone model.  In this communication, we present the results of experiments 
designed to provide baseline knowledge of cuprizone-induced demyelination and 
remyelination, comparing morphological and cellular changes in male and female C57BL/6 
mice.  Although the data indicate no significant sex differences in several measures of 
demyelination and remyelination, we observed that cuprizone intoxication disrupts estrous 
cyclicity in female mice. Thus, cuprizone may interfere with potential endogenous hormone 
influences on demyelination and remyelination in this strain, perhaps interfering with innate 
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sex differences.   
 
 
3.3 MATERIALS AND METHODS 
 
Animals and cuprizone treatment:  Adult male and female C57BL/6 mice were purchased 
from Jackson Laboratories (Bar Harbor, ME).  At 8 weeks of age mice were fed ad libitum 
0.2% cuprizone (oxalic bis(cyclohexylidenehydrazide)) (Sigma-Aldrich) mixed into ground 
or pelleted Purina mouse chow for 3 weeks to induce partial demyelination or 5 weeks to 
induce maximal demyelination.  In keeping with previous studies [162, 165, 166], 
remyelination was assessed by returning mice to a diet of normal Purina pellet chow for one 
week, after 6 full weeks of cuprizone treatment. Untreated control mice were fed ground or 
pelleted Purina chow during the time that experimental mice were being treated with 
cuprizone.  
 
Tissue Preparation: For light microscopy, mice were deeply anesthetized and intracardially 
perfused with 0.15M phosphate buffer followed by 4% paraformaldehyde (PFA) solution. 
After overnight fixation in PFA, brains were removed, dehydrated and embedded in paraffin.  
Tissues were processed and embedded at the UNC Lineberger Animal Histopathology Core 
Facility.  5µm coronal brain sections were cut at the fornix region of the corpus callosum, 
(approximately Bregma -0.5mm to -0.7mm) and corresponding to Figure 37 of The Mouse 
Brain In Sterotaxic Coordinates [181].  For electron microscopy, mice were deeply 
anesthetized and intracardially perfused with 0.15M phosphate buffer followed by a 4% 
glutaraldehyde/ 2% PFA solution. Brains were removed, post fixed for two weeks and 
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embedded in resin.  A coronal block of brain was cut at the fornix region of the corpus 
callosum, as described above.  A sagittal cut was then made at the midline, and tissue was 
embedded in resin such that the cross sections of the axonal fibers could be visualized.   
Luxol Fast Blue – Periodic Acid Schiff’s (LFB-PAS) stain: To examine demyelination and 
remyelination, paraffin sections were stained with Luxol fast blue (Sigma, St. Louis, MI), 
which stains myelin blue, and periodic acid-Schiff (Sigma, St. Louis, MI), which stains 
microglia/macrophages and demyelinated axons pink.  Sections were scored blinded based 
on the ratio of blue or pink fibers in the corpus callosum, on a scale from 3 (complete 
myelination equal to an untreated mouse) to 0 (complete demyelination, as seen during peak 
cuprizone demyelination).  The region of corpus callosum analyzed is midline, directly above 
the fornix in a coronal section at approximately Bregma -0.5mm to -0.7mm .  See manuscript 
by Mason and colleagues [162] for a cartoon of the region analyzed. 
 
Immunohistochemistry: For immunohistochemistry, 5um paraffin sections were 
deparaffinized and rehydrated.  Phosphate buffered saline (PBS) was used in all rinsing steps.  
Mature oligodendrocytes were detected with a polyclonal antibody to the Pi isoform of 
glutathione S-transferase (GSTpi) (Biotrin, Newton, MA).  A biotin conjugated lectin, 
Ricinus communis agglutin-1 (RCA-1) (Vector Laboratories Inc, Burlingame, CA), was used 
to detect microglia/macrophages.  Astrocytes were detected with antibody to glial fibrillary 
acidic protein (GFAP) (Invitrogen).  
For GSTpi staining, sections were first permeabilized/blocked with 0.1% Triton X-
100/ 2% normal goat serum in PBS for 20 minutes at room temperature.  Antigen retrieval 
was performed with 0.1% trypsin/ 0.1% calcium chloride in 0.05M Tris, pH 7.4 for 10 
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minutes at 37ºC.  Following rinsing, sections were incubated with GSTpi antibody (1:1000 in 
block) or isotype control overnight at 4oC.  For RCA-1 and GFAP staining, sections 
underwent antigen retrieval with 0.025% protease, type XIV (Sigma-Aldrich) for 2 minutes 
at 43 oC.  After rinsing, sections were incubated in blocking solution (0.1% Triton X-100 and 
1% bovine serum albumin for RCA-1 or 2% normal goat serum for GFAP in PBS) for 1 hour 
at room temperature.  To detect microglia, sections were then incubated overnight at 4oC 
with RCA-1, 1:500 in blocking solution, or blocking solution alone as a control.  For GFAP 
staining, sections were incubated with GFAP antibody (1:200 in blocking solution) or isotype 
control overnight at 4oC.   
After incubation in the primary detection reagents described above, sections were 
incubated with the appropriate AlexaFluor conjugated secondary antibody (1:400) 
(Molecular Probes, Eugene, OR), for 1 hour at room temp.  Sections were then rinsed and 
mounted with Vectasheild medium containing the nuclear counter stain 4',6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories Inc, Burlingame, CA). Fluorescent staining was 
visualized using a Nikon (Tokyo, Japan) Optiphot FXA microscope with epifluorescence 
optics.  All comparative analyses were focused in the median corpus callosum in a region of 
0.21mm wide and 0.15mm to 0.30mm high (the corpus callosum area becomes larger with 
infiltrating cells during demyelination). Positive-stained cells were counted only if a nucleus 
was observed and were quantified per square mm. 
 
Detection of apoptotic oligodendrocytes:   Apoptosis of oligodendrocytes in the corpus 
callosum was determined by labeling DNA strand breaks by Terminal deoxynucleotidyl 
transferase (TUNEL reaction) co-localized with GSTpi immunostaining as a marker for 
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mature oligodendrocytes.  GSTpi immunohistochemistry was performed as described above, 
followed by detection of apoptotic nuclei using the In Situ Cell Death Detection Kit, 
Fluorescein (Cat# 11 684 795 910) (Roche Diagnostics, Mannheim, Germany) with a one 
hour incubation at 37oC in TUNEL reaction mixture prepared as described in manufacturer’s 
protocol except for a 1:3 dilution of Enzyme solution in TUNEL Dilution Buffer (cat# 11 
966 006 001) (Roche Diagnostics, Mannheim, Germany). 
 
Electron microscopy: Ultrathin sections were cut, stained with lead citrate and uranyl acetate 
and electron micrographs obtained using Zeiss EM910 Transmission Electron Microscope 
with a digital camera at the Microscopy Services Laboratory in the UNC Department of 
Pathology and Laboratory Medicine.  Greater than 500 axons (0.3µm or greater diameter) 
from each animal were counted as myelinated or unmyelinated and the percentage of 
myelinated axons out of total axons is given as percent myelination. 
Statistical analysis:  Statistical comparisons were made using two-way ANOVA with 
Bonferroni post-test or, where indicated, by Student’s t test. The data are expressed as mean 
+ SEM. 
 
Monitoring of estrous cyclicity by vaginal cytology:  Samples were collected daily by vaginal 
lavage with PBS, analyzed by phase-contrast microscopy and scored for the stage of the 
estrous cycle, based on number of each cell type, as described by Allen [203], as follows: 
proestrus = mostly smooth epithelial cells, estrus = cornified epithelial cells, diestrus = 






Female C57BL/6J mice demyelinate and remyelinate to a similar extent as male 
counterparts.   
 
Five weeks of cuprizone treatment is known to produce maximum demyelination in 
the midline corpus callosum of male C57BL/6 mice [148] and remyelination begins by week 
6 of cuprizone treatment [166, 174, 204].  Remyelination continues if cuprizone treatment is 
withdrawn after week 6 [165, 166].  Our first objective was to determine whether this pattern 
is similar in female mice.  Eight week old mice of each sex were fed either normal chow 
(untreated), or 0.2% cuprizone to induce demyelination, assessed at 3 or 5 weeks, or treated 
for 6 weeks followed by one week of normal chow to assess remyelination (represented in 
the figures as “6+1wk”).  At each time point, mice were sacrificed and brains collected for 
light microscopy or electron microscopy analysis. 
For an initial assessment of myelination, paraffin-embedded brain sections were 
stained for myelination with the Luxol Fast Blue-Periodic Acid Schiff’s (LFB-PAS) stain.  
Myelinated fibers are stained blue (Figure 3.1A, Untreated), and unmyelinated fibers appear 
pink (Figure 3.1A, 5 wk cuprizone).  The sections were scored blinded, in the midline region 
of the corpus callosum using a scale from 0 to 3 in which 3 represents normal myelination, 
and 0 represents complete demyelination.  We found that females exhibit less demyelination 
at the 3 week time point than males, though this difference was not statistically significant 
(Figure 3.1A and Figure 3.1B).  By 5 weeks, both males and females reached nearly full 
demyelination, with no difference between the sexes.  At the 6+1 week remyelination time 
point, in which the mice have been off the cuprizone diet for 1 week, partial remyelination 
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occurred similarly with no statistical difference between males and females (Figure 3.1A and 
Figure 3.1B). 
To obtain a more accurate and quantitative measure of myelination, we analyzed 
cross-sections of corpus callosum axons by electron microscopy.   For each animal, greater 
than 500 axons were counted as myelinated or unmyelinated and the percentage of 
myelinated axons was computed and averaged for each group.  The results shown in Figure 
3.2A and Figure 3.2B confirm the light microscopy data in Figure 3.1.  Prior to treatment, 
male and female mice have similar numbers of myelinated axons.  Upon exposure to 
cuprizone, the number of myelinated fibers at week 3 and maximal demyelination observed 
at week 5 were similar.  Furthermore, remyelination progressed similarly between male and 
female mice.  Thus, no significant differences in demyelination or remyelination were 




Figure 3.1. Cuprizone-induced demyelination and remyelination in male and female 
C57BL/6 mice.   
A. Representative images of LFB-PAS stained midline corpus callosum sections.  
Magnification is 40x and scale bar represents 50 micrometers.   
B. Myelination scores obtained by blinded scoring of midline corpus callosum sections 
stained with LFB-PAS.  A score of 3 reflects normal myelination in an untreated mouse, 
whereas a score of 0 reflects the absence of myelin, similar to 5wk (as depicted in part A). 




Figure 3.2. Myelinated and demyelinated axons in male and female C57BL/6 mice.   
A. Representative electron micrographs of corpus callosum axons during cuprizone 
treatment.  Magnification is 10,000x and scale bar represents 2 micrometers.   
B.  Percent myelinated axons in corpus callosum electron micrographs obtained by counting 
greater than 500 axons per animal. Mean and SEM bars for percent of total axons that are 








Female C57BL/6 exhibit no differences in mature oligodendrocytes loss during 
demyelination or oligodendrocyte repopulation during remyelination compared to male 
counterparts. 
 
Depletion of mature oligodendrocytes is a feature of cuprizone-induced 
demyelination in male C57BL/6 mice [162].  Mature oligodendrocytes were detected by 
immunohistochemistry with an antibody to glutathion-S-transferase pi isoform (GSTpi) and 
those associated with a nucleus were quantified.  The number of GSTpi-positive cells in the 
midline corpus callosum was similar in untreated male and female mice (Figure 3.3A and 
3.3B).  After 3 weeks of cuprizone treatment, male and female mice exhibit a similar loss of 
oligodendrocytes in the corpus callosum, as determined by the total number of 
oligodendrocytes (Figure 3.3A and 3.3B) as well as the number of apoptotic 
oligodendrocytes (Figure 3.3C).  At 5 weeks, the time of maximal demyelination, very few 
mature oligodendrocytes are found in the midline corpus callosum of either sex.  During 
remyelination, female and male mice exhibit a similar extent of repopulation of mature 
oligodendrocytes in the corpus callosum (Figure 3.3A and 3.3B). 
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Figure 3.3.  Cuprizone-induced loss of oligodendrocytes and subsequent repopulation during 
recovery in corpus callosum of male and female C57BL/6 mice.   
A. Representative images of GSTpi+ mature oligodendrocytes in the corpus callosum of male 
and female mice during cuprizone treatment and recovery. Magnification is 40x and scale bar 
represents 50 micrometers.   
B. Quantification of GSTpi+ mature oligodendrocytes in the corpus callosum of male and 
female mice during cuprizone treatment and recovery.  Mean and SEM bars plotted for 10-16 
mice per sex at each time point.   
C. Quantification of apoptotic oligodendrocytes in the corpus callosum.  Mean 
GSTpi+/TUNEL+ cells per square millimeter and SEM bars plotted for 12 animals per sex 













Female C57BL/6 exhibit no difference in the accumulation of microglia in the corpus 
callosum during demyelination or remyelination compared to male counterparts.  
 
Microglia accumulate in the corpus callosum presumably to clear debris during 
demyelination and provide trophic factors that support remyelination.  Histochemical 
staining using the lectin RCA-1 (a marker for microglia/ macrophage) was performed on 
paraffin-embedded brain sections.  The number of RCA-1-positive cells in the midline 
corpus callosum were counted and averaged for each group.  There are very few microglia in 
the corpus callosum of normal male and female mice and the number of microglia are similar 
between the sexes (Figure 3.4A and 3.4B).   During demyelination, microglia accumulate at 
week 3 and reach maximal numbers at week 5, when demyelination is also maximal.  
However, no significant difference was observed between male and female mice in the 
accumulation of microglia/macrophages in the corpus callosum during demyelination.  
During remyelination the presence of microglia/macrophages diminished to a similar extent 
in male and female mice (Figure 3.4). 
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Figure 3.4. Accumulation of microglia in the corpus callosum of male and female C57BL/6 
mice.   
A. Representative images of RCA-1 histochemical staining of microglia/macrophages in the 
corpus callosum of mice during cuprizone treatment and recovery.  Magnification is 40x and 
scale bar represents 50 micrometers.   
B. Quantification of RCA-1+ microglia/macrophages in the corpus callosum.   Mean RCA-1+ 









Female C57BL/6 exhibit no difference in the accumulation of astrocytes in the corpus 
callosum during demyelination or remyelination compared to male counterparts   
 
Astrocytes are present at low numbers in normal adult mice and accumulate in the 
corpus callosum similar to microglia during demyelination and remyelination.  
Immunohistochemical staining using an antibody to GFAP, a marker for astrocytes, was also 
performed here and the number of GFAP-positive cells in the midline corpus callosum was 
counted and averaged for each group.  There are astrocytes in the corpus callosum of 
untreated mice; however, male and female mice have similar numbers (Figure 3.5A and 
3.5B).  During demyelination, astrocyte numbers increase at week 3 and reach a peak by 
week 5.  There were no significant sex differences in the accumulation of astrocytes in the 
corpus callosum during demyelination, although there was a trend for a slightly higher 
number of astrocytes in female mice.  Similarly, female mice had slightly higher numbers of 
astrocytes during remyelination (Figure 3.5).  However, these differences did not reach 




Figure 3.5.  Accumulation of astrocytes in the corpus callosum of male and female C57BL/6 
mice.   
A. Representative images of GFAP immunohistochemical staining of astrocytes in the corpus 
callosum of mice during cuprizone treatment and recovery.  Magnification is 40x and scale 
bar represents 50 micrometers.   
B.  Quantification of GFAP + astrocytes in the corpus callosum.  Mean GFAP+ cells per 
square millimeter and SEM bars plotted for 10-16 animals per sex at each time point. 
 
 
Cuprizone treatment disrupts estrous cyclicity in female mice.   
A previous study in our laboratory determined that a 0.2% dose of cuprizone 
treatment in male C57BL/6J mice causes minimal weight loss and no histologically 
detectable liver toxicity [161]. However, to our knowledge, gonadal tissues and function 
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have not been assessed for cuprizone toxicity in any strain or sex of rodent.  In female mice, 
this can be readily approached using an in vivo assay of hormone status; i.e., by monitoring 
estrous cyclicity by vaginal cytology [108].  This technique is well established in rodents and 
is performed by daily collection of vaginal cells by gentle saline lavage of the vaginal cavity.  
Phase contrast analysis of the number and type of cells present in the sample indicates which 
phase of the four to five day estrous cycle the mouse is undergoing (Figure 3.6A, top).  We 
began by monitoring estrous cycling in female mice 2 weeks prior to cuprizone treatment.  
Because the standard procedure for cuprizone treatment is to use 8-10 week old mice, we 
began our vaginal cytology analysis in 6-7 week old mice.  Mice of this age are just 
beginning to cycle regularly and there is some variability in the length of cycle.  Only female 
mice that displayed a 4-6 day estrous cycle in the two weeks prior to cuprizone treatment 
were included in the study.   
 In order to determine whether cuprizone treatment adversely affects estrous cycling, 
vaginal cell samples were collected every day at the same time during the 6 week cuprizone 
treatment and compared to untreated mice that were monitored concurrently.  The data are 
plotted in Figure 3.6B, as the number of estrus phases (the phase that corresponds to 
ovulation) detected every 7 days, so that we could assess the cycling pattern relative to 
number of weeks on cuprizone treatment.  In a normal cycling mouse, an estrus phase should 
occur every 4-5 days, so this would result in a score of approximately 1.4 estrus phases per 7 
days.  Prior to cuprizone treatment, female mice displayed a relatively regular estrous cycle, 
with estrus occurring every 4-6 days.  This pattern continued in the untreated mice.  In 
contrast, in cuprizone-treated mice, a dramatic change in estrous cyclicity occurred, indicated 
by representative images of vaginal cell samples in Figure 3.6A and the drop in number of 
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estrus phases per week as shown in Figure 6B.  By the second week of cuprizone treatment, 
no estrus phases were detected for the duration of the 6 week treatment, with the exception of 
2 out of 13 mice.   
Upon removal of cuprizone from the diet, female mice began displaying an estrus 
phase within the first week or two, and cycles became regular by the 3rd or 4th week off the 
cuprizone diet (Figure 3.6B).  This ability to recover estrous cycling indicates that the 
reproductive tissue was not irreversibly damaged by cuprizone toxicity. 
 
 
Figure 3.6. Cuprizone treatment reduces the number of estrus phases compared to the same 
mice before treatment or untreated mice monitored concurrently. 
Estrous cycling was monitored by scoring of vaginal cytology.   
A. Top: representative samples from untreated female mice (P = proestrus, E = estrus, M = 
metestrus, D = diestrus). Bottom: representative samples collected from cuprizone-treated 
female mice during weeks 2-6. Magnification is 40x and scale bar represents 50 micrometers.   
B. Number of estrus phases detected per 7 days in mice monitored for 2 weeks before 
cuprizone, during 6 weeks of cuprizone treatment, and during recovery from cuprizone, or 





Reproductive tissues of female mice are affected by cuprizone. 
To corroborate the data obtained by analysis of vaginal cytology, female reproductive 
organs were weighed.  It is known that uterine weight fluctuates with the estrous cycle and is 
reflective of estradiol levels, such that it is highest during proestrus, begins falling during 
estrus, is lowest during metestrus and rises again during diestrus [205, 206].  Furthermore, 
uterine weight is often used as a bioassay of estrogenic activity [207, 208]. The wet weights 
of uteri + ovaries were obtained from cuprizone-treated or untreated mice sacrificed at the 5 
week time point when demyelination is maximal and estrous cycling was disrupted (Figure 
3.6B).  At sacrifice, uterine weights in untreated mice correlated with the phase of the estrous 
cycle (data not shown).  All of the cuprizone-treated mice had reduced uterine + ovary 
weights  (Figure 3.7B), with average weights showing a 2-3 fold reduction compared with 
untreated females (Figure 3.7A and 3.7B).  Four weeks after cuprizone removal from the 
diet, uterine + ovary wet weights have returned to levels equivalent to untreated mice, 
mirroring the return of estrous cyclicity shown in Figure 3.6B.  These observations of 
disrupted estrous cyclicity and reduced uterine weight suggest that circulating hormone 
levels may not be normal in cuprizone treated mice.  Furthermore, testes weights were 
obtained for male mice treated with cuprizone for 5 weeks, and were compared to untreated 
and remyelinating mice (Figure 3.7C).  There was no significant change in testes weights in 
the cuprizone treated male mice.   
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Figure 3.7. Cuprizone treatment results in diminished weights of female but not male sex 
organs.     
A. Representative images of uteri + ovaries from untreated female mice (upper) and 5 week 
cuprizone treated female mice (lower).  
B. Wet weights of uteri + ovaries obtained from untreated (5wk UT, circles) and cuprizone-
treated female mice at 5 weeks (5wk cuprizone, squares) as well as 10 week untreated (10wk 
UT, circles) or mice that were treated with cuprizone for 6 weeks followed by 4 weeks of 
normal diet (6 + 4wk recov, triangles). Sex organ weights are significantly diminished by 5 
weeks of cuprizone treatment (* p<0.001 compared to 5wk UT by student’s t test) but return 
to untreated weights 4 weeks after removal of cuprizone from the diet.   
C. Wet weights of testes from 5 week untreated (5wk UT, circles), 5 week cuprizone treated 
(squares), and remyelinating (6 + 1 recov, triangles) mice which were treated with cuprizone 
for 6 weeks followed by 1 week of normal diet.  There are no statistical differences in testes 







Cuprizone intoxication in C57BL/6 male mice has been increasingly used as a model 
to study oligodendrocyte loss and demyelination, as well as remyelination, in the CNS.  We 
noted previously that C57BL/6 female mice were susceptible to demyelination, in contrast to 
earlier reports for female Swiss mice [146, 148].  Although investigators have begun using 
female C57BL/6 mice to study cuprizone-induced CNS disease and have shown them to be 
susceptible to demyelination, to our knowledge, no direct comparisons between males and 
females of this strain have been made.  We report here that, similar to male C57BL/6 mice, 
females develop extensive demyelination by week 5 of cuprizone treatment.  Although there 
was a trend for less severe demyelination at week 3 in female mice, detected by LFB-PAS 
staining, the difference was not statistically significant.  In addition, analyses at the electron 
microscope level indicated no differences in demyelination or remyelination between female 
and male mice.  Similarly, oligodendrocyte depletion and recovery was the same between 
females and males.  Microglial and astrocyte responses also appeared equal.  Interestingly, 
cuprizone treatment disrupted estrous cyclicity, which may indicate a perturbation in the sex 
hormone status of cuprizone treated female mice. No change in male reproductive tissue was 
observed. 
Sex differences have been characterized in other rodent models of demyelinating 
disease, particularly EAE.  Most studies of sexual dimorphism in EAE are carried out the 
SJL mouse strain, in which females show an increase in susceptibility and severity of disease 
[42, 46, 63, 209].  However, in other strains, males exhibit increased susceptibility (B10.PL 
and PL/J) or no sex differences (NOD/lt and C57BL/6) [46].  Likewise, the TMEV model 
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displays sex differences that vary by strain. An early study in the C57BL/J mouse strain 
demonstrated that female mice are completely resistant to TMEV-induced demyelinating 
disease [200].  This was later shown to be due to a more robust anti-viral response to the 
initial infection by female mice [70]. In the SJL mouse strain, both males and females are 
susceptible, but male mice demonstrate more severe neurological deficits [69]. Given the 
variation by strain in sex differences in these models, it is possible that another mouse strain 
may show sex differences in the cuprizone model.  Indeed, we have recently investigated sex 
differences in the cuprizone model in SJL mice and found that females exhibit less severe 
oligodendrocyte loss and demyelination [210]. 
Sex may also play a role in remyelination, as demonstrated by Li and colleagues [73].  
In this study ethidium bromide was used to induce death of oligodendrocytes in young and 
old male and female adult rats.  Remyelination is less efficient in older animals.  While no 
sex difference in remyelination was observed in young adult rats, remyelination was better in 
older females compared with males. Removal of the gonads prior to demyelination did not 
affect remyelination in young or old male or female rats, suggesting that gonadal sources of 
sex hormones did not influence remyelination. However, another study using this model 
demonstrated a modest increase in remyelination in aged male rats treated with progesterone.  
Most cuprizone studies, including the present one, are performed in young adult rodents.  
Thus, it would be of interest to determine if sex differences in cuprizone-induced disease 
occur in older mice.   
An interesting finding in this study is that cuprizone intoxication disrupts estrous 
cyclicity, accompanied by diminished weights in the sex organs in female mice.  To our 
knowledge, this is the first indication that the estrous cycle is affected during cuprizone 
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treatment, and indicates that circulating sex hormone levels are not normal in treated female 
mice.  Whether cuprizone directly affects gonadal tissue, or whether disruption of the estrous 
cycle is a side effect of the moderate loss in body weight that occurs, is not known.  It is also 
possible that cuprizone alters steroid hormone biosynthesis or metabolism.  Based on wet 
weight measurements of testes in male mice, it does not appear that cuprizone has a 
detrimental effect on male reproductive tissue.  In the future, it would be of interest to 
measure the levels of circulating steroid hormones to more completely assess hormone status, 
and if specific changes are detected, to determine if they vary with mouse strain. These data 
suggest that future studies of sex differences in demyelination and remyelination using this 
model may require hormone replacement strategies and/or analysis of mechanisms of 
hormone metabolism.   Another factor to consider is the possibility that cuprizone toxicity 
has a different effect on sex steroid synthesis in the brain, compared with the periphery.  It is 
well known that CNS cells are capable of de novo synthesis and metabolism of sex steroids, 
and that the enzymes responsible for their synthesis are upregulated after brain injury 
(reviewed in [116]).  Since female C57BL/6 mice appear to demyelinate and remyelinate 
similarly to male mice, it seems unlikely that endogenous sex hormones play a major role in 
the pathogenesis of cuprizone intoxication in this mouse strain.   
Consistent with a lack of a sex difference in demyelination, we found that the 
microglial and astroglial responses were similar in female and male mice.  The temporal 
pattern of oligodendrocyte depletion and recovery, and the accumulation of microglia and of 
astrocytes in female mice suggest a lack of inherent differences in these cells when compared 
to male mice.  In conclusion, female C57BL/6 mice exhibit no significant sex differences in 
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cuprizone-induced demyelination or remyelination and this may be explained by the finding 









 In addition to regulating reproductive functions in the brain and periphery, estrogen 
also has trophic and neuroprotective functions in the central nervous system (CNS).  
Estrogen administration has been demonstrated to provide protection in several animal 
models of CNS disorders, including stroke, brain injury, epilepsy, Parkinson’s disease, 
Alzheimer’s disease, age-related cognitive decline and Multiple Sclerosis.  Here, we use a 
model of toxin-induced oligodendrocyte death which results in demyelination, reactive 
gliosis, recruitment of oligodendrocyte precursor cells and subsequent remyelination to study 
the potential benefit of 17β-estradiol (E2) administration to male mice.   The results indicate 
that E2 partially ameliorates loss of oligodendrocytes and demyelination of the corpus 
callosum, and this protection is accompanied by a delay in microglia accumulation as well as 
reduced mRNA expression of the pro-inflammatory cytokine tumor necrosis factor alpha 
(TNFα) and the growth factor insulin-like growth factor -1 (IGF-1).  E2 did not significantly 
alter the accumulation of astrocytes or oligodendrocyte precursor cells, or remyelination.  
This work sets the stage for more detailed analysis of the mechanism by which E2 protects 





 Interest in the use of sex hormones for therapy to treat Multiple Sclerosis (MS) stems 
from the observation that disease is partially ameliorated during pregnancy.  A large 
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prospective European PRIMS study of 227 female MS patients showed a significant decrease 
in disease relapses during pregnancy, especially during the third trimester, compared to the 
relapse rate in these same women before they became pregnant [13].  In addition, the relapse 
rate significantly increased in the 3 months post-partum, before returning to pre-pregnancy 
levels.  This finding suggests a protective role for pregnancy-related factors, one of which 
could be sex steroids.  In fact, the estrogen derivative estriol, which is produced by the 
placenta and is present in high levels in maternal serum during pregnancy, was recently 
examined for potential benefit to MS patients in a clinical trial [79].  The pregnancy level of 
oral estriol that was delivered to a small number of female MS patients was able to reduce 
the number and volume of lesions as seen by magnetic resonance imaging (MRI). 
 The data from animal models of demyelinating disease and in vitro studies provides 
further evidence for a potential benefit of estrogens.  Two forms of estrogen, estriol and 17β-
estradiol (E2), have been shown to reduce clinical symptoms of experimental autoimmune 
encephalomyelitis (EAE), an accepted model of MS [66, 88, 89].  A direct role for estrogen 
in oligodendrocytes, the cells responsible for central nervous system (CNS) myelination, has 
been demonstrated.  Addition of E2 to rodent primary oligodendrocyte cultures led to 
increased proliferation of oligodendrocyte precursors and enhanced membrane sheet 
formation, [117, 131, 132].  E2 also prevents toxin and oxygen-mediated death of 
oligodendrocytes in culture and oxygen-mediated loss of MBP in neonatal rat white matter 
[133, 134].  Furthermore, sex steroids may have a role in mediating demyelinating disease 
through anti-inflammatory mechanisms.  E2 has anti-inflammatory effects on microglia 
cultures, by reducing expression of inducible nitric oxide synthase and several other 
inflammatory mediators in response to LPS and to proinflammatory cytokines [135, 136, 
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138, 211].  Estrogen also protects against neuronal death from brain injury, 
neurodegeneration associated with Alzheimer’s disease and Parkinson’s disease, age-related 
cognitive decline, and epilepsy [212-216].  Furthermore, E2 and estrogen receptor ligands 
administered during EAE prevented axonal loss in the white matter and neuronal pathology 
in gray matter, highlighting the potential benefit of estrogen in preserving neuronal integrity 
in demyelinating disease [96, 217]. 
 In an effort to determine the role of estrogen in primary oligodendrocyte death and 
CNS demyelination, we have administered E2 to male C57BL/6 mice during-cuprizone 
induced demyelination and remyelination.  We used male mice to avoid estrogen fluctuation 
during cycling in female mice and because demyelination is well characterized in C57BL/6 
males [161].  Cuprizone causes death of oligodendrocytes, demyelination and infiltration of 
reactive glia to the lesion, as well as accumulation of oligodendrocyte precursor cells (OPCs) 
[148, 161, 162].  Remyelination occurs spontaneously by six weeks of treatment, and 
proceeds rapidly if cuprizone intoxication is discontinued [163, 165, 166].   We report that 
E2 was effective in producing a partial amelioration of oligodendrocyte loss and 
demyelination, but did not alter remyelination.  Furthermore, E2 treatment produced a delay 
in microglia accumulation and a reduction in levels of IGF-1 and TNFα mRNA.     
 
 
4.3 MATERIALS AND METHODS 
 
Animals and cuprizone treatment:  Adult male C57BL/6J mice were purchased from Jackson 
Laboratories (Bar Harbor, ME) and used for experiments at 8 weeks of age.  Mice were 
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housed in DLAM facilities under sterile pathogen-free conditions.  To induce demyelination, 
cuprizone (oxalic bis(cyclohexylidenehydrazide)) (Sigma-Aldrich) at a concentration of 
0.125% was mixed into ground Purina mouse chow and fed ad libitum for 3 to 5 weeks. 
Remyelination was assessed by returning the mice to a diet of normal chow for one week 
following 6 weeks of cuprizone administration. Control mice (labeled “untreated”) were fed 
pelleted Purina chow and were sacrificed at the same time as the 5 week cuprizone group. All 
animal use was performed in compliance with the NIH Guide for Care and Use of 
Laboratory Animals and approved by the UNC-CH Institutional Animal Care and Use 
Committee.  
 
17β-estradiol administration:  Continuous release 25 mg 17β-estradiol (E2) or placebo 
pellets (3x4 mm; Innovative Research of America, Sarasota, FL) were implanted 
subcutaneously by sterile surgical procedure on the backs of mice between the shoulder 
blades.  These pellets are designed to release continuously over a 60 day period, which would 
calculate to 0.42 mg/day.  Cuprizone treatment began 5 days after implantation. 
 
Serum 17β-estradiol measurement: Serum was obtained from whole blood samples by 
centrifugation after removal of blood clot and stored at -80oC until use.  E2 was measured by 
radioimmunoassay (RIA) using the double antibody estradiol kit (cat# KE2D5, Seimens, Los 
Angeles, CA) and following the manufacturer protocol. 
 
Tissue Preparation: For histology, mice were deeply anesthetized using isoflurane and 
intracardially perfused with 0.15M phosphate buffer followed by 4% paraformaldehyde 
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(PFA) solution. Brains were removed, post-fixed overnight in PFA, and embedded in 
paraffin or post-fixed for 4 hours in PFA, followed by 1-2 days in 30% sucrose, and then 
embedded in Tissue-Tek® O.C.T.™ freezing media (Sakura Finetek, Torrance, CA) and 
frozen on a bed of dry ice.  Five µm paraffin or frozen coronal brain sections were cut at the 
fornix region of the corpus callosum (approximately Bregma -0.5mm to -0.7mm) and 
corresponding to Figure 37 of The Mouse Brain In Sterotaxic Coordinates [181].   
For the isolation of mRNA, corpus callosum tissue was obtained by making coronal 
cuts at approximately Bregma -0.25mm and -1.25mm.  Then sagittal cuts through the 
cingulum, on the inside of each lateral ventricle were performed followed by a cut above and 
below the corpus callosum to remove the majority of cortex and fornix.  This block of tissue 
was immediately submerged in RNAlater solution (cat#AM7020, Applied Biosystems, 
Foster City, CA) and after overnight 4oC incubation, stored at -80o C until use.  The corpus 
callosum of five brains was combined for each sample. 
 
Luxol Fast Blue – Periodic Acid Schiff’s (LFB-PAS) stain: To examine demyelination and 
remyelination, paraffin or frozen sections were stained with Luxol fast blue (Sigma, St. 
Louis, MI), which stains myelin blue, and periodic acid-Schiff (Sigma, St. Louis, MI), which 
stains microglia/macrophages and demyelinated axons.  Sections were scored blinded based 
on the amount of blue or pink fibers in the corpus callosum, on a scale from 3 (complete 
myelination equal to an untreated mouse) to 0 (complete demyelination, as seen during peak 
cuprizone demyelination at week 5).  The region analyzed was the midline corpus callosum, 
as diagramed previously in Figure 1 of Mason et al. [162].   
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Immunohistochemistry: The detection of mature oligodendrocytes was performed with 
antibody to the Pi isoform of glutathione S-transferase (GST ) (Biotrin, Newton, MA).  
Paraffin or frozen sections were permeabilized with 0.1% Triton X-100/ 2% normal goat 
serum in phosphate-buffered saline (PBS) for 20 minutes at room temperature.  Antigen 
retrieval to better expose the antibody-binding epitope was performed with 0.1% calcium 
chloride/ 0.1% trypsin in 0.05M Tris, pH 7.4 for 15 minutes at 37oC.  Sections were rinsed in 
PBS and incubated with anti-GSTpi antibody (1:1000) or isotype control overnight at 4o C.   
Oligodendrocyte precursor cells were detected with a rabbit antibody to NG2, 
generously supplied by Dr. W.B. Stallcup (Genomic Institute of Novartis Res. Foundation, 
CA).  Five micrometer frozen sections were fixed in 95% ethanol before being stored at -80 
oC.  Upon removal from the freezer, sections were post-fixed in cold acetone, rinsed in 
potassium-phosphate-buffered saline (KPBS), and blocked with 0.1% Triton X-100/ 5% 
normal goat serum in KPBS for 1 hour at room temperature.  Sections were then incubated 
with anti-NG2 antibody (1:500 in blocking solution) or isotype control overnight at 4o C.   
Microglia/macrophages were detected with biotinylated lectin Ricinus communis 
agglutin-1 (RCA-1) (Vector Laboratories Inc, Burlingame, CA).  Paraffin or frozen sections 
were unmasked with 0.025% protease, type XIV (Sigma-Aldrich) for 2 minutes at 43o C. 
Following a brief rinse in PBS, they were blocked with 0.1% Triton X-100/ 1% bovine serum 
albumin in PBS for 1 hour at room temperature.  Sections were then incubated with RCA-1, 
1:500 in blocking solution or blocking solution alone as a control, overnight at 4o C.   
Astrocytes were detected with antibody to glial fibrillary acidic protein (GFAP) 
(Invitrogen). Paraffin sections were rehydrated and unmasked with 0.025% protease, type 
XIV (Sigma-Aldrich) for 2 minutes at 43o C. Following a brief rinse in PBS they were 
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blocked with 0.1% Triton X-100/ 2% normal goat serum in PBS for 1 hour at room 
temperature.  Sections were then incubated with anti-GFAP antibody (1:200) or isotype 
control overnight at 4o C.   
Following incubation in the primary detection agent, all immunohistochemistry was 
completed by first rinsing sections three times in PBS, then incubating for 1 hour at room 
temp with the appropriate secondary antibody (1:400) conjugated to AlexaFluor (Molecular 
Probes, Eugene, OR).  After rinsing, sections were cover-slipped with Vectasheild plus DAPI 
(Vector Laboratories Inc, Burlingame, CA) to counter stain nuclei. 
All comparative analyses were focused in the corpus callosum at the midline.   An 
Olympus (Melville, NY) BX40 microscope, Olympus DP70 digital camera and 
ImageProPlus software (Media Cybernetics, Silver Spring, MD) were used to obtain images.  
The images of the fluorescent antibody staining were overlayed with DAPI images and 
immunohistochemically positive cells which colocalized with a nucleus were quantified per 
square mm.   
 
Semi-quantitative real-time PCR:  RNA was obtained from corpus callosum tissue (see 
above), which was pooled for 5 animals per treatment group, by manual homogenization in 
Trizol (Invitrogen, Carlsbad, CA) and cleaned up with RNeasy Mini kit (cat# 74104, Qiagen, 
Valencia, CA).  TaqMan 5’ nuclease real-time PCR assays were performed using an ABI 
Prism 7500 sequence-detection system (PE Applied Biosystems, Foster City, CA) in the 
UNC Neuroscience Center Functional Genomics Core Facilty.  For IGF-1 analysis the 
Taqman® Gene Expression Assay system was used (ID# Mm00439559_m1), which includes 
proprietary sequences (Applied Biosystems, Foster City, CA).  For TNFα analysis custom 
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oligonucleotide primer and TMRATM probe sequences were as follows (Applied Biosystems, 
Foster City, CA):  
TNFα primer-forward: CATCTTCTCAAAATTCGAGTGACAA;  
TNFα primer-reverse: CTCCAGCTGCTCCTCCACTT;  
TNFα Probe: CCTGTAGCCCACGTCGTAGCAAACCAC 
 
Statistical analysis:  Statistical analysis was performed using two-tailed Student’s t test. 





Serum levels of E2 in mice implanted with continuous release hormone pellets. 
In order to determine the effect of E2 on demyelination and remyelination, male 
C57BL/6 mice were implanted subcutaneously with continuous release placebo or pellets 
containing 25 mg E2 designed to release a consistent amount of hormone over 60 days (0.42 
mg/day).  Blood was collected from a representative sample of mice 4 days following 
implantation and cuprizone treatment began the following day, except for control mice which 
continued on a normal diet.  Serum was collected again prior to sacrifice after 3, 5 or 7 weeks 
of the demyelination experimentation.  Serum levels of E2 were measured by RIA.   
 Four days after implantation, serum E2 rose rapidly and reached an average of about 
3000 pg/mL in the groups of mice with E2 implants (Figure 4.1).  In contrast, mice without 
implants did not show detectable levels of E2.  After 3 or 5 weeks of cuprizone treatment, the 
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average serum E2 was 4000 to 5000 pg/mL and similar levels were reached in the mice not 
receiving cuprizone.  By the 7 week time point, average serum E2 had diminished slightly to 
3500 pg/mL.  These levels of serum E2 correspond to the lower range reported for pregnant 
mice (5000-10,000 pg/mL) [218].  Serum E2 in the placebo implanted mice was nearly 
always below the detection limit of the RIA assay, but when detectable, a range from 5-




Figure 4.1.  Serum E2 of male mice implanted with continuous release E2 pellets. 
Serum was collected 4 days after subcutaneous implantation of 25 mg/60 day continuous 
release E2 pellets, as well as at the time of sacrifice from mice that were not exposed to 
cuprizone, or exposed to cuprizone for 3 weeks, 5 weeks, or 6 weeks plus 1 week of 
discontinuation of cuprizone.  Measurement of E2 in the serum was conducted by RIA.  
Results indicate that serum levels of E2 approached the range reported for pregnant mice, 




E2 partially ameliorates cuprizone-induced demyelination. 
 The affect of E2 on demyelination was assessed by exposing mice to cuprizone five 
days after implantation of placebo or E2 pellets. Mice were analyzed for demyelination after 
3 or 5 weeks of cuprizone treatment when male C57BL/6 are known to be partially or fully 
demyelinated, respectively [161].   After 3 weeks of cuprizone administration, E2 treated 
mice are significantly less demyelinated than placebo controls (Figure 4.2A and 4.2B).  This 
effect continues at the 5 week time point in which the E2-treated mice showed significantly 
less demyelination.   
A visual analysis of the individual myelin scores during demyelination, indicate that 
E2 was effective in attenuating demyelination in a sub-population of the mice to which it was 
administered.  These data points are indicated with gray circles in Figure 4.2B.  At the five 
week time point, there is a clear difference between mice that are almost fully demyelinated 
(black circles) and those which had myelin scores greater than any of the placebo treated 
mice (gray circles).  Although variance in myelin scores of placebo treated mice at the 3 
week time point is greater, there is still a population of E2 treated mice which all have myelin 
scores greater than any of the placebo treated mice.   
The reason for the variability in the protective effect of E2 is unclear, but could be a 
result of the confounding factor of the way cuprizone is administered, i.e. mixed into chow 
that is fed ad libitum.  Thus, if some mice are ingesting more cuprizone than others, the 
increased exposure to the toxin may overcome the protective effect of E2.  The effectiveness 
of E2 to attenuate demyelination did not correlate with the level of serum E2 measured at the 
time of sacrifice (data not shown).  In the subsequent analysis of cellular populations of these 
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mice laid out in this manuscript, the mice that showed a protection from demyelination (gray 
circles) will continue to be colored gray so that their cellular profiles may be followed. 
 Interestingly, after 1 week of recovery from cuprizone, the placebo-treated mice that 
showed greater demyelination at week 5 began to remyelinate substantially.  However, the 
E2-treated mice display an average myelin score very similar to their 5 week time point 
(Figure 4.2B).  This suggested that remyelination may be partly delayed since demyelination 















Figure 4.2.  Demyelination and remyelination in placebo and E2-treated mice. 
A. Representative images of LFB-PAS-stained midline corpus callosum sections.  
Magnification is 40x and scale bar represents 50 micrometers.   
B. Myelination scores obtained by blind-scoring of midline corpus callosum sections stained 
with LFB-PAS.  A score of 3 reflects normal myelination in an untreated mouse, whereas a 
score of 0 reflects the absence of myelin. Individual data points and mean bars are plotted for 
10-15 animals per group at each time point.  * p < 0.05.  At the 3 and 5 week time points, E2-
treated mice that exhibited the greatest protection from demyelination are indicated with gray 
circles so that they may be followed in the subsequent figures of this manuscript. 
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E2 preserves oligodendrocytes. 
 In addition to myelination, the number of oligodendrocytes was examined in corpus 
callosum sections by immunohistochemistry to the marker GSTpi, which allows visualization 
of mature oligodendrocyte cell bodies (Figure 4.3A).  Equal numbers of oligodendrocytes 
were detected in mice that did not receive cuprizone (Figure 4.3B).  Similar to what was seen 
in the myelin histological stain (Figure 4.2B), more oligodendrocytes are present in E2-
treated mice at 3 and 5 weeks of cuprizone treatment, though statistical significance was 
reached only at the 5 week time point (p< 0.05; Figure 4.3A and 4.3B).  This suggests that 
this hormone results in partial protection of oligodendrocytes from cuprizone toxicity.   
The E2-treated group of mice at week 5 in Figure 4.2B could be segregated into non-
responders and those mice that responded to E2 treatment.  A visual analysis of the E2-
treated mice which showed a protection from demyelination (gray dots in Figure 4.2B) 
indicates that these mice also tended to have greater preservation of oligodendrocytes (Figure 
4.3B), particularly at the 5 week time point.  This would strengthen our correlation that 
responses to E2 treatment provide a noticeable protection for mature oligodendrocyte 
preservation.  
The mature oligodendrocytes repopulating the demyelinated lesions were also 
quantified.  After 1 week of recovery from cuprizone, oligodendrocyte numbers are restored 
to levels near that of the untreated mice.  Although there are no statistically significant 
differences between the groups, there appears to be slightly fewer mature oligodendrocytes in 






Figure 4.3.  Cuprizone-induced loss of oligodendrocytes and subsequent repopulation during 
recovery in placebo and E2-treated mice.  
A. Representative images of GSTpi+ mature oligodendrocytes in the corpus callosum of 
placebo and E2-treated mice during cuprizone administration and recovery.  Magnification is 
40x and scale bar represents 50 micrometers.   
B. Quantification of GSTpi+ mature oligodendrocytes.  Individual data points and mean bars 
are plotted for 10-15 animals per group at each time point.  * p < 0.05.  At the 3 and 5 week 
time points, E2-treated mice that exhibited the greatest protection from demyelination 
(Figure 4.2B) are indicated with gray circles. 
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E2 does not affect the number of oligodendrocyte precursor cells in 
demyelinating/remyelinating lesions of treated mice. 
 
 In vitro studies indicate that E2 can promote proliferation of oligodendrocytes [131].  
Therefore, we hypothesized that numbers of oligodendrocyte precursor cells (OPCs) would 
be greater in demyelinated lesions of E2-treated mice.  OPCs were detected by 
immunohistochemistry to the marker NG2.  Contrary to our expectations, there was no 
statistically significant difference in numbers of OPCs in the lesions of E2-treated mice 
compared to placebo, at any of the time points (Figure 4.4). However, a following of the 
mice that showed protection from demyelination (gray circles) indicates that when E2 was 
most effective at reducing demyelination, there were fewer OPCs accumulating in the corpus 
callosum.  As OPCs transition to mature oligodendrocytes at 1 week of recovery, they are 
reduced in numbers as expected and are diminished simlarly in placebo and E2-treated mice.   









Figure 4.4.  Accumulation of OPCs during demyelination and remyelination in placebo and 
E2-treated mice.  
A. Representative images of NG2+ OPCs in the corpus callosum of placebo and E2-treated 
mice during cuprizone administration and recovery.  Magnification is 40x and scale bar 
represents 50 micrometers.   
B. Quantification of NG2+ OPCs.  Individual data points and mean bars are plotted for 8-10 
animals per group at each time point.  There are no statistically significant differences 
between placebo and E2-treated mice at any time point.   At the 3 and 5 week time points, 
E2-treated mice that exhibited the greatest protection from demyelination (Figure 4.2B) are 
indicated with gray circles. 
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Accumulation of microglia/macrophages is delayed in E2-treated mice. 
  Microglia, and to a lesser extent macrophage, activation and accumulation in 
demyelinated lesions is a hallmark feature in cuprizone-induced demyelination [161, 219].  
These cells phagocytize myelin debris as well as produce a variety of cytokines and other 
molecules which may both exacerbate cuprizone-induced demyelination, and promote the 
repair process [147, 164, 165, 174, 189, 220-222].  Here, histochemical staining was 
performed with the lectin RCA-1, a marker for microglia/macrophages, in the corpus 
callosum during the time course of demyelination and remyelination.  Very few microglia 
were present in mice that have not been exposed to cuprizone, and this was not altered by E2 
treatment (Figure 4.5).  After three weeks of cuprizone treatment, there were significantly 
fewer microglia in the demyelinated lesion of E2-treated versus placebo-treated mice.  This 
pattern correlates with the decreased demyelination of E2-treated mice (Figure 4.2).  
However, by 5 weeks of cuprizone intoxication, there were similar numbers of microglia 
present in placebo and E2-treated mice, despite the decreased demyelination in E2-treated 
mice at this time point. An analysis of the mice that showed protection from demyelination 
(gray circles) indicated no clear pattern at the 3 week time point, but a distinct skewing 
towards fewer microglia in the less demyelinated lesions at 5 weeks.  During remyelination, 
the microglia population was diminished to a similar extent in both placebo and E2-treated 






Figure 4.5.  Accumulation of microglia during demyelination and remyelination in placebo 
and E2-treated mice.  
A. Representative images of RCA-1+ microglia/macrophages in the corpus callosum of 
placebo and E2-treated mice during cuprizone administration and recovery.  Magnification is 
40x and scale bar represents 50 micrometers.   
B. Quantification of RCA-1+ microglia/macrophages.  Individual data points and mean bars 
are plotted for 10-15 animals per group at each time point.  * p < 0.05.  At the 3 and 5 week 
time points, E2-treated mice that exhibited the greatest protection from demyelination 
(Figure 4.2B) are indicated with gray circles. 
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E2 does not affect numbers of astrocytes during demyelination or remyelination. 
 Astrocytes respond to demyelination and also secrete cytokines and growth factors 
that participate in cuprizone-induced demyelination and remyelination [162, 170, 182, 189, 
221, 223].  Similar to microglia, immunostaining with the astrocyte marker GFAP was 
performed to examine whether E2 affects the numbers of these cells during demyelination 
and remyelination.  In untreated mice, there are few astrocytes present in the corpus 
callosum.  During demyelination, the astrocyte population increased similarly in placebo and 
E2-treated mice (Figure 4.6).  Very similar to the observation of microglia accumulation, 
there appears to be no obvious correlation with protection from demyelination (gray circles) 
and astrocyte number at 3 weeks; however, at the 5 week time point, these mice showed a 
decreased astrocyte accumulation correlating with the less demyelinated lesions.  E2 had no 










Figure 4.6.  Accumulation of astrocytes during demyelination and remyelination in placebo 
and E2-treated mice.  
A. Representative images of GFAP+ astrocytes in the corpus callosum of placebo and E2-
treated mice during cuprizone administration and recovery.  Magnification is 40x and scale 
bar represents 50 micrometers.   
B. Quantification of GFAP+ astrocytes.  Individual data points and mean bars are plotted for 
10-15 animals per group at each time point.  There are no statistically significant differences 
between placebo and E2-treated mice at any time point.  At the 3 and 5 week time points, E2-
treated mice that exhibited the greatest protection from demyelination (Figure 4.2B) are 
indicated with gray circles. 
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TNFα and IGF-1m RNA expression is diminished in E2-treated mice during 
demyelination. 
 
 In an effort to determine potential mechanisms of E2 protection against cuprizone-
induced demyelination and oligodendrocyte loss, mRNA expression of two candidate 
mediators was measured by semi-quantitative PCR analysis.  Due to the small amount of 
tissue of isolated corpus callosum and variability of E2 to produce protection from 
demyelination (Figure 4.2B), corpus callosi of 5 mice per group were pooled for RNA 
analysis.  TNFα is an inflammatory cytokine that has been associated both with exacerbation 
of demyelinating disease [91, 165, 224] as well as having an important beneficial role in 
remyelination [165].  Furthermore, estrogen is known to regulate expression of TNFα [90, 
211, 225].  Therefore, we sought to determine whether TNFα expression was altered by E2 
administration during cuprizone-induced demyelination or remyelination.   
Previous studies have shown that TNFα is upregulated during cuprizone-induced 
demyelination, and is primarily expressed by microglia, and occasionally by astrocytes [165].  
Analysis of mRNA expression by semi-quantitative PCR indicated that in placebo-treated 
mice an expected increase of TNFα occurred during demyelination (70-fold compared to 
untreated placebo at 3 weeks and 90-fold compared to untreated placebo at 5 weeks of 
cuprizone treatment (Figure 4.7A).  During remyelination, TNFα levels were reduced, which 
corresponds to the reduction in microglia and astrocytes at this time point (Figure 4.5B).  
Interestingly, E2 treatment reduced the upregulation of TNFα during demyelination by one 
third at 3 weeks and two thirds compared to placebo at 5 weeks of cuprizone treatment.  This 
reduction in TNFα correlated with the reduced mature oligodendrocyte death from E2-
treated mice. 
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 IGF-1 is a growth factor which is expressed by most astrocytes and a sub-population 
of microglia during cuprizone-induced demyelination [189], and has been demonstrated to 
promote oligodendrocyte survival and promote remyelination [164, 167].  Therefore, we 
wanted to investigate the expression of IGF-1 in E2-treated mice during demyelination and 
remyelination.  Results of semi-quantitative PCR indicated that levels of IGF-1 mRNA 
increase during demyelination in placebo-treated mice (Figure 4.7B) and decrease during 
remyelination, similar to previous results in unmanipulated mice subjected to cuprizone 
intoxication [162].  When mice were exposed to E2 administration, IGF-1 mRNA was 
substantially attenuated at both 3 and 5 weeks of demyelination (Figure 4.7B).  This 








Figure 4.7.  mRNA expression of TNFα and IGF-1 during demyelination and remyelination 
in placebo and E2 treated mice.  
A. Semi-quantitative real-time PCR analysis of TNFα mRNA indicates the expected 
upregulation during demyelination in placebo treated mice, which is reduced by 
approximately half in E2 treated mice.  All samples are normalized to the untreated placebo 
group. 
B. Semi-quantitative real-time PCR analysis of IGF-1 mRNA indicates the expected 
upregulation during demyelination in placebo treated mice, which is dramatically reduced in 






 The sex hormone E2 has been demonstrated to reduce neuronal loss and 
demyelination in several models of CNS injury [96, 212, 226, 227], as well as a prevent 
oligodendrocyte cell death and promote proliferation of oligodendrocyte precursors in vitro 
[131, 133, 134].  In this study, we used a toxin model of primary oligodendrocyte death to 
evaluate the role of E2 in CNS demyelination and remyelination.  We report that E2 
administration to male mice partially ameliorated corpus callosum demyelination and 
reduced mature oligodendrocyte loss.  This protection was accompanied by a delay in 
microglia accumulation in the demyelinating lesion as well as reduced IGF-1 and TNFα 
expression.  However, there was no statistically significant effect on numbers of 
oligodendrocyte precursors or astrocytes that infiltrated the lesion.  In addition, E2 did not 
alter remyelination. 
 The two general mechanisms by which E2 may be attenuating demyelination include 
a direct anti-apoptotic effect in the mature oligodendrocytes, or an anti-inflammatory 
mechanism mediated by microglia and astrocytes.  Both of these scenarios are plausible, 
given that E2 has been demonstrated to prevent death of oligodendrocytes and neurons in 
vivo [134, 228-231] as well as inhibit glial activation and inflammation in the CNS [139, 232, 
233].  Furthermore, immunohistochemical expression of both estrogen receptor-alpha (ERα) 
and estrogen receptor-beta (ERβ) has been demonstrated in brain cells: neurons and 
astrocytes can express either ERα or ERβ in vivo [229, 234, 235],  oligodendrocytes and the 
myelin sheath co-localize in vivo with ERβ [123], and ERα has been demonstrated in 
microglia in vivo [125].  Attempts to co-localize ERα and ERβ in oligodendrocytes, 
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microglia and astrocytes in the corpus callosum during cuprizone-induced demyelination and 
remyelination have been unsuccessful so far.  Nonetheless, a combination of direct protection 
of mature oligodendrocytes by E2 and reduced noxious products from microglia such as 
TNFα may be contributing to the reduced demyelination. 
The ability of E2 to reduce demyelination has previously been demonstrated in the 
EAE model, and is generally thought to produce it effects by anti-inflammatory mechanisms 
of the immune system and by preventing infiltration of reactive T cells into the CNS [88-90]. 
Using ERα or ERβ deficient mice as well as selective agonists to each receptor, the anti-
inflammatory and clinical symptom reduction effects of E2 in EAE was demonstrated to be 
mediated by ERα, but not through ERα in T cells [93-95].  In addition, it was recently shown 
that E2, and both ERα and ERβ agonists have neuroprotective effects in EAE [96, 217].  
Relatively little attention has been given to effects of E2 in oligodendrocytes in EAE studies.  
Here, we have demonstrated that E2 can also reduce demyelination and prevent loss of 
oligodendrocytes in a toxin model of demyelination.  Studies with ERα- and ERβ-deficient 
mice are currently underway to determine the contribution of each of these receptors to the 
observed protection.  
E2 has been shown to attenuate hyperoxia-mediated loss of MBP in rat pups in vivo 
as well as hyperoxia-induced apoptotic death of primary oligodendrocytes in vitro [134]. 
Using the in vitro model, this group demonstrated that E2 inhibited hyperoxia-induced 
proapoptitic Fas-upregulation and caspase-3 activation and antagonized hyperoxia-induced 
inactivation of extracellular signal-regulated kinase 1 and 2 (ERK1 and 2) and Akt, key 
kinases of the mitogen activated protein kinase (MAPK) and phosphatidylinositol 3-kinase 
(PI3K) cell survival-promoting pathways, respectively. Therefore, a potential mechanism to 
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explain the beneficial effects of E2 in cuprizone-induced demyelination may be an inhibition 
of apoptosis in oligodendrocytes.  Future studies to measure expression of pro- and anti-
apoptotic mediators localized to mature oligodendrocytes may provide important insights 
into the mechanism of E2 protection in cuprizone-induced demyelination.  
 Though E2 has been shown to increase proliferation of oligodendrocyte precursors in 
vitro [131, 236], we did not see an increase in OPCs in our E2 treated mice.  In fact, in the 
mice in which E2 produced the most protection from demyelination, there were fewer OPCs 
in the lesion than in any of the other mice (Figure 4.4B, gray circles).  The most likely 
interpretation for this observation is that OPCs were not called into the lesion, because there 
was less damage to the mature oligodendrocytes, and hence, there is less need for repair.  
This phenomenon has been seen in IGF-1 transgenic mice [164] and nNOS-/- mice [237], 
where there was very little loss of mature oligodendrocytes in the demyelinating lesion, and 
subsequently very little accumulation of OPCs.  Alternatively, the reduction of TNFα in E2-
treated mice shown here may be at least partly responsible for diminishing OPC numbers, 
given that cuprizone-treated TNFα-deficient mice display a significant reduction in 
accumulation and proliferation of OPCs during demyelination [165]. 
 Quantification of microglia and astrocytes during cuprizone-induced demyelination 
and remyelination indicated that overall E2 resulted in a delay of microglia accumulation, but 
had no effect on astrocyte numbers in the corpus callosum.  However, an analysis of the mice 
that showed the greatest protection from demyelination by E2 indicated that there was a 
reduction in both of these cell types, especially at the 5 week time point (Figures 4.5B and 
4.6B, gray circles).  This begs the difficult question: is there less gliosis because there is less 
demyelination and oligodendrocyte perturbation to respond to, or is there less demyelination 
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because of a reduction in the cells that produce pro-inflammatory cytokines which may have 
toxic effects to oligodendrocytes?  Evidence that microglia are responsible for cuprizone-
induced demyelination comes from a study which demonstrated that microglia inactivation 
by minocycline significantly attenuated demyelination [147].  In addition to a delay in 
microglia accumulation, we have demonstrated a reduction in TNFα mRNA in E2-treated 
mice.  If one assumes a similar reduction in protein levels, this attenuation in microglial 
response may be a mechanism to explain the protective effect of E2, since it has previously 
been shown that demyelination is delayed in TNFα-deficient mice [165].  Alternatively, the 
reduction in TNFα may simply reflect that the microglia are less activated, due to the 
reduction in demyelination. 
 We have also demonstrated that E2-treatement attenuated demyelination-induced 
upregulation of IGF-1 expression.  IGF-1 is a growth factor which is a survival factor for 
oligodendrocytes [164, 238, 239] and promotes remyelination [167].  There is evidence for 
cross-talk between the actions of estradiol and insulin-like growth factor –1 (IGF-1) in 
several neural events, such as: survival of developing neurons, neuronal differentiation, 
synaptic plasticity, female sexual behavior, adult neurogenesis, and neuroprotection 
(reviewed in [240]; [241]; [242]).  However, the effects of E2 on the expression of IGF-1 are 
mixed, with a few reports of E2 administration resulting in increased IGF-1 expression in 
various tissues [243-245] and others reporting a reduction [246, 247].  Whether the reduction 
of IGF-1 mRNA expression during cuprizone-induced demyelination demonstrated here is 
directly mediated by E2 or is a result of reduced activation of microglia and astrocytes, is not 
known.  Although in our subgroup of mice that showed protection from demyelination with 
E2 (Figure 4.2B), these animals had reduced numbers of microglia which may suggest a 
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diminished immune insult on mature oligodendrocytes.  Both in vitro and in vivo studies 
have indicated that IGF-1 can protect oligodendrocytes from TNFα-mediated death [239, 
248].  Therefore, the reduced IGF-1 expression may be due to a reduced need for protection. 
Future studies using mice with specific elimination of TNFR1 or IGF-1R on mature 
oligodendrocytes may indicate whether one or both mechanisms are employed. 
Studies of brain injury indicate that the neuronal survival mediated by estradiol or 
IGF-1 each depend on the co-activation of ER and IGF-1 receptor ([230]; [229]).  Both in 
vitro and in vivo studies have shown that estradiol regulates the expression of IGF-1 
receptors in neural tissue ([240]; [249]).  Furthermore, estradiol has been shown to regulate 
several downstream mediators of IGF-1 signaling, including extracellular-signal-regulated 
kinase (ERK), phosphoinositide 3-kinase (PI3K), the kinase Akt, and glycogen synthase 
kinase 3β (GSK3β) [112] [250]; [251] [252]; [241]; also see [242] for review) and acts 
synergistically with IGF-1 to increase Akt in rat brain [251].  IGF-1 may also act 
synergistically with E2 to prevent SIN-1-mediated death of oligodendrocytes in vitro [133].  
Therefore studies are planned to measure expression/phosporylation of the IGF-1 receptor 
and downstream signaling molecules such as those of the PI3K and MAPK pathway in these 
E2-treated brain samples, particularly on mature oligodendrocytes. 
In conclusion, we have demonstrated that E2 administration to male mice provides a 
partial protection from oligodendrocyte loss and demyelination.  This protection may be due 
to a combination of a delay in microglia accumulation and a reduction in TNFα and IGF-1 




CONCLUSIONS AND FUTURE DIRECTIONS
 122 
The goal of this dissertation work was to provide insights into sex differences and the 
potential therapeutic benefit of estrogen in demyelinating disease.  These issues are currently 
the focus of active research in many disciplines including autoimmune diseases and 
neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke, 
epilepsy and traumatic brain injury.  Use of the cuprizone model to explore the role of sex 
and sex hormones may provide information applicable to other conditions in addition to MS 
which display some oligodendrocyte death, dysfunction, or demyelination such as AD, 
Huntington’s disease, spinal cord injury, and the irradiated CNS [253-261].  We have 
demonstrated that cuprizone-induced demyelination is characterized by strain dependant sex 
differences, and that administration of a pregnancy level of 17β-estradiol (E2) is effective in 
partially reducing oligodendrocyte loss and demyelination in male mice.  Future studies to 
expose potential mechanisms of these sex differences, E2 effects, and therapeutic potential 
are described in this final chapter of the dissertation. 
 
Female SJL exhibit less severe cuprizone-induced demyelination. 
 Sex differences in cuprizone-induced demyelination were analyzed in the SJL mouse 
strain, which has previously demonstrated sex differences in other models of demyelination.  
We have demonstrated that SJL females exhibit a modest protection from demyelination and 
loss of oligodendrocytes at several points during a time course of cuprizone administration.  
However, there was no sex difference in the numbers of OPCs, microglia, or astrocytes that 
accumulated in the corpus callosum lesions.  Furthermore, a preliminary study of 
remyelination indicated that there was no difference in remyelination at the particular time 
point tested. 
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 In order to determine whether circulating sex hormones are responsible for this sex 
difference, gonadectomies/adrenalectomies could be performed.  One would want to test both 
sexes, since either male or female sex hormones could mediate disease, as has been 
demonstrated in EAE.  Furthermore, replacement of individual hormones after 
gonadectomy/adrenalectomy would provide more conclusive evidence for the role of that 
particular hormone.  If a particular hormone was found to mediate the sex difference in 
demyelination severity, further studies would be needed to determine it’s mechanism of 
action.  One potential method is to use gene microarray analysis to compare gene expression 
between male and female corpus callosum lesions.   
The role of sex chromosomes could be tested by using XX and XY- ovary bearing 
females, and XY-Sry and XX Sry testes bearing males which give one the ability to study the 
effect of the sex chromosome makeup on the background of both female and male hormones.  
Use of this model in SJL mice demonstrated that the XX chromosome makeup lead to more 
severe EAE, and was associated with reduced expression of Th2 cytokines IL-4, IL-10 and 
IL-13 [38].   
  
Temporal and regional differences in demyelination patterns in SJL mice. 
An interesting finding that came out of the study of SJL sex differences is that this 
strain displays temporal and severity differences in demyelination compared to C57BL/6 
mice.  In beginning to work with the SJL, we first performed a cuprizone dose titration, from 
which it was determined that 0.2% cuprizone produced the most demyelination without overt 
systemic toxicity.  The dose titration was analyzed after 5 weeks of cuprizone administration, 
since this is the time point at which maximal demyelination occurs in the corpus callosum of 
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C57BL/6 mice.  We found that at this time point, SJL mice did not display maximal 
demyelination.  Therefore, we next performed a time course of continuous cuprizone 
exposure, analyzing demyelination at weekly intervals from 3 to 10 weeks.  Both male and 
female SJL gradually demyelinated during this time period never achieving full 
demyelination.  There was also less accumulation of microglia and astrocytes in the SJL 
demyelinating lesions than is typical for C57BL/6.  We found that even after 13 weeks of 
continuous cuprizone exposure, demyelination was not significantly different than at the 10 
week time point (data not shown).  Maximum loss of oligodendrocytes occurred after 7 
weeks of cuprizone exposure, compared to 5 weeks in C57BL/6 mice.  Furthermore, a 
preliminary study of remyelination suggests that SJL are slower to remyelinate than C57BL/6 
mice. This strain difference in demyelination severity indicates that there might be genetic 
differences between SJL and C57BL/6 mice which partially protect SJL from cuprizone-
induced death of oligodendrocytes.  One way to analyze a genetic influence on cuprizone-
induced demyelination severity would be to use recombinant inbreeding between SJL and 
C57BL/6 and analyze the crossed offspring to identify quantitative trait loci (QTL) 
controlling demyelination severity.  This approach has been used in the EAE model, in 
crosses between the highly susceptible SJL/J and resistant C57BL/10.2 mice [262-266] and 
was successful in identifying several QTL that regulate parameters such as disease onset, 
severity, and cell infiltration during EAE in mice.   
 In addition to the difference in time course and severity of demyelination in the SJL 
strain, there was an interesting difference in regional demyelination within the corpus 
callosum.  Whereas C57BL/6 display robust demyelination in the medial region of a coronal 
section of corpus callosum, SJL mice demonstrate a preservation of myelinated fibers at the 
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midline, and in the lower part of the more lateral regions, just above the fornix (see Figure 
2.1).  The reason for this heterogeneity of demyelination is far from clear, but speculation 
results in the following potential mechanisms.  One potential explanation is that axons 
coming from different regions of the cortex may provide different levels of trophic signals to 
the oligodendrocytes myelinating them.  Although the literature does not reveal any evidence 
for a pro-survival signal from axons to oligodendrocytes which are already fully mature and 
myelinating, there is certainly evidence that axons provide pro-survival cues to immature 
oligodendrocytes, such as through neuregulin [267-269].  Alternatively, different neuronal 
populations may be more or less perturbed by the cuprizone insult and hence producing 
different levels of toxic factors which affect the oligodendrocytes myelinating them.  It is 
known that cuprizone intoxication results in some axonal pathology [145, 174, 270] but 
whether this occurs before or after the axon has become demyelinated is not known. Another 
possibility is that there are different levels of secreted factors of a protective or exacerbatory 
nature coming into the corpus callosum from the neighboring brain regions.  Alternatively, 
there may be regional differences in penetration of the cuprizone toxin.  
  A synthesis of the findings from demyelination in C57BL/6 versus SJL mice indicate 
that there are genetic differences which mediate sex effects as well as demyelination patterns 
and severity.  These strain differences may have important implications for genetic 
influences on demyelination in an outbred human population and may mediate some of the 





Lack of sex differences in demyelination/remyelination in C57BL/6 mice. 
  
The results from the work of chapter 3 of this dissertation demonstrate that female 
C57BL/6 female mice exhibit an equivalent pattern of cuprizone-induced demyelination and 
remyelination as their male counterparts.  The possible exception to this was that LFB-PAS 
histological staining at the 3 week time point indicated a trend for decreased demyelination in 
the female mice.  However, quantification of myelinated axons from electron micrographs at 
this time point indicated no significant differences between males and females.  Furthermore, 
there were no significant differences in the numbers of oligodendrocytes in the demyelinating 
or remyelinating corpus callosum lesion at any time point.  Accordingly, the numbers of 
microglia and astrocytes which accumulate in the lesion were equivalent.  The results of this 
work are closely aligned with that of the EAE model, whereby it has been demonstrated that 
C57BL/6 mice do not exhibit sex differences in susceptibility or severity of demyelinating 
disease [44, 46]. 
 Interestingly, it was determined that cuprizone intoxication disrupted the estrous 
cycle in these mice, beginning in the first two weeks.  This disruption was reversible, as 
females resumed a normal estrous cyclicity within 4 weeks of discontinuation of cuprizone 
administration.  Because estrous cyclicity and uterine weight is an excellent bioassay for sex 
hormone function [108, 205-208], it is assumed that circulating levels of sex hormones are 
altered in cuprizone treated female mice.  However, this was not directly measured, and 
would be an important step in any future studies of gender or the role of sex hormones in the 
cuprizone model.  Furthermore, a disruption in circulating hormone levels could possibly be 
attenuated in the brain, since many CNS cells have the ability to produce sex [77, 271] 
 127 
steroids.  The mechanism of cuprizone’s effect on estrous cyclicity is not known.  Possible 
explanations include: a toxic effect to ovarian cells which produce the hormones that control 
estrous cyclicity; a disruption of the steroid biosynthesis pathway; or a general effect of the 
stress and weight loss that occurs in cuprizone-intoxicated mice.   
In an effort to determine whether reproductive functions of male mice might be 
similarly perturbed, testes weights were analyzed.  There was no significant difference in the 
weights of testes between cuprizone treated and age-matched controls.  However, this 
method of analysis may not be as sensitive a measure of sex hormone function as is the 
vaginal lavage and uterine weight assays used in the female mice.  Therefore, further analysis 
would have to be performed to conclude without a doubt that sex hormone function was not 
perturbed in the male mice.  This could be done by measuring serum levels of sex hormones 
and performing histological analysis of the testes tissue.   
Overall, this finding that cuprizone disrupts estrous cyclicity in C57BL/6 mice 
presents a limitation to the use of the cuprizone model in the study of sex differences.  Based 
on the findings of the previous chapter, the glaringly obvious question is: was estrous 
cyclicity disrupted in female SJL mice?  Unfortunately, this question remains to be answered.  
The cuprizone studies in SJL mice were performed before the estrous cyclicity assays were 
performed in C57BL/6 mice.  However, measures of estrous cyclicity and sex hormone 






E2 partially prevents oligodendrocyte loss and demyelination. 
 In order to ascertain whether E2 has protection functions during demyelination in 
vivo, we administered pregnancy levels of E2 to male mice during cuprizone administration, 
in the form of subcutaneously implanted continuous release pellets.  We have demonstrated 
that E2 was effective in reducing oligodendrocyte loss and demyelination.  This protection 
was accompanied by a delay in microglia accumulation as well as a significant reduction in 
TNFα and IGF-1 mRNA.  Treatment with E2 did not significantly alter numbers of OPCs or 
astrocytes which accumulated in the lesion, nor was remyelination significantly different at 
the 7 week time point. 
 Currently, several experiments are under way that should help elucidate a mechanism 
for this protection by E2.  In order to determine which estrogen receptor is involved, ERα 
and ERβ deficient mice (designated αERKO, and βERKO) were implanted with placebo or 
E2 pellets, and treated with cuprizone for 5 weeks.   If one or the other receptor is solely 
responsible for the protection by E2, then we will not see any protection by E2 in those 
knock-out mice.  Two potential caveats exist which may prevent this experiment from 
conclusively determining the role of these receptors.  First, if they compensate for each other, 
we may see protection in both knock outs.  In this case, we will have to conclude that either 
there is compensation, or that E2 is working through an estrogen receptor-independent 
mechanism, such as through its antioxidant actions (reviewed in [212]).  Since cuprizone-
intoxication is associated with oxidative stress [142, 147, 272, 273], a potential antioxidative 
effect of estradiol is intriguing.  In order to evaluate whether the receptors are compensating 
for each other, double knockout mice could be generated.  We have tried this in the past, 
however due to the fact that these mice must be bred as heterozygotes, since the monozygous 
 129 
knockouts are infertile, it requires very large numbers of breeding pairs to obtain enough 
double knockouts of similar age to use for an experiment.  Alternatively, administration of 
the ER antagonist ICI 182 780 (selective for both ER subtypes) at the same time as the E2 
treatment could be performed.  The other caveat is that we have seen a frustrating amount of 
variability in the response of individual mice to the E2 treatment, such that only 6 of 15 mice 
were significantly protected from demyelination at the 5 week time point.  Therefore, only if 
significant numbers of the wild type mice show protection in this experiment will we be able 
to make a conclusion about the knockout mice.  We have included 7-8 placebo treated and 7-
8 E2 treated male mice of each genotype (wild type C57BL/6, αERKO, and βERKO) for this 
analysis. 
 Determining the expression of ERα and ERβ in the corpus callosum and during 
cuprizone-induced demyelination is an important step in elucidating the mechanism of action 
of E2 in this model.  I have made several attempts at immunohistochemical analysis of 
expression of these receptors, but so far have been unsuccessful.  Currently, we are in the 
process of testing additional tissue processing methods, and perhaps additional antibodies, 
and hope to be able to obtain co-localization data in the near future.  In the meantime, 
analysis of mRNA expression by RT-PCR and protein expression by western blot will be 
performed.  In this way we will have an idea of the relative levels of expression of each 
receptor in an untreated corpus callosum and during demyelination and remyelination. 
 In addition, further analysis using the mRNA and protein collected from these 
experiments will be used to measure the expression levels of various candidates potentially 
mediating the effects of E2 in this system.  We have already demonstrated that TNFα 
expression is reduced in E2 treated mice, and this may have important consequences, since 
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TNFα deficient mice have been shown to exhibit less severe EAE [91], and a delay in 
cuprizone-induced demyelination [165]. Therefore, a downregulation of TNFα by E2 may 
lead to reduced oligodendrocyte death. Next, we will determine whether expression of TNF 
receptor 1 (TNFR1) or TNFR2 are altered by E2 administration.  TNFR1 is a death receptor 
which mediates cell death, or potentially cell survival [274-276], whereas TNFR2 can 
enhance cell death through TNFR1 or promote survival [277, 278] but has also been 
demonstrated to be important for proliferation of oligodendrocytes and remyelination [165].  
Estrogen administration has been shown to decrease TNFR1 in PC12 cells [226], but 
increased expression of TNFR1 and decreased TNFR2 in a rodent ischemia model [279].  It 
should be noted that a decrease in TNFα signaling presents potential inhibition to 
remyelination.  It was demonstrated by Arnett and colleagues that in TNFα and TNFR2 
deficient mice,  proliferation of OPCs and repopulation of mature oligodendrocytes was 
decreased [165].  Though we did not detect a significant decrease in OPC numbers, or 
remyelination, this potential inhibition of remyelination should remain a concern during 
future studies. 
 We have also demonstrated that E2 administration led to a reduction in IGF-1 
expression.  The significance of this reduction is not clear, and a review of the literature 
regarding E2/IGF-1 crosstalk in neuroprotection suggests that regulation of IGF-1 receptor or 
downstream signaling may be a better measure of the potential benefits of E2 administration.  
We hypothesize that IGF-1R will be increased in mature oligodendrocytes with E2 treatment 
and may participate in the protection from death mediated by E2.  We plan to measure this by 
Western blot and immunochemical co-localization with mature oligodendrocytes.  In the 
future, we hope to assess the activation state of the receptor by assessing levels of the 
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phosphorylated protein.  Futhermore, our lab already possess some of the reagents necessary 
to perform western blot analysis of the expression of phosphorylated downstream mediators 
of IGF-1R signaling, namely ERK and Akt.   
In addition, we would like to further characterize the potential role of E2 in 
preventing apoptosis of oligodendrocytes by looking at mediators of apoptosis that have been 
demonstrated to be regulated by E2 in models of neuroprotection, such as Bcl-2, Bcl-xL, and 
Bax, [280-283].  
  
Working Model 
The work presented here regarding the potential therapeutic benefit of E2 in 
demyelinating disease leads to a working model with two alternative (or potentially additive) 
mechanisms (Figure 5.1).  First, E2 may be preventing the accumulation and activation of 
microglia and astrocytes in the corpus callosum, and preventing the production of pro-
inflammatory mediators which exacerbate oligodendrocyte death.  This model is supported 
by the finding that oligodendrocytes in culture are not killed by the addition of cuprizone 
unless TNFα is also added [147].  Furthermore, mice that are deficient for TNFα experience 
a delay in cuprizone-induced demyelination [165].  Second, E2 may have a pro-survival 
effect in oligodendrocytes, thus directly preventing cuprizone-induced death and subsequent 
demyelination.  In the absence of dying oligodendrocytes and myelin debris, fewer astrocytes 
and microglia are activated to accumulate in the lesion and thus there is a reduction in 
production of mediators such as TNFα and IGF-1.  In support of this mechanism, E2 has 
been demonstrated to protect oligodendrocytes from oxygen-mediated and toxin-induced 
death in vitro, through anti-apoptotic mechanisms [133, 134].   
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Astrocytes, microglia, and oligodendrocytes have been shown to express estrogen 
receptors in several other systems (see section 1.5), however, an analysis of their expression 
in the corpus callosum in response to cuprizone-induced demyelination may shed further 
light on which of the proposed models is more likely.  Assuming all of these cell types do 
express the estrogen receptors in this scenario, one way to determine whether E2 is acting 
primarily through an anti-inflammatory or pro-survival mechanism would be to engineer 
conditional knockout mice in which the estrogen receptors are ablated from either 
oligodendrocytes or microglia and astrocytes.  This could be accomplished with the cre-lox 
system using cell type specific promoters (PLP for oligodendrocytes, GFAP for astrocytes, 
CD11b for microglia).  Ideally, one would also like to make the ablation inducible, so that 
developmental effects do not complicate the ability to draw conclusions during injury and 






Figure 5.1.  Two potential models to explain E2 reduction of cuprizone-induced 
oligodendrocyte loss, demyelination, microglia and astrocyte accumulation and expression of 
TNFα and IGF-1.   
The left panel describes the potential anti-inflammatory affect of E2, and the subsequent 
reduction in inflammatory mediators such as TNFα which may contribute to oligodendrocyte 
death and demyelination.  The right panel illustrates the potential pro-survival affect of E2 in 
oligodendrocytes, which would limit demyelination and subsequent activation of microglia 
and astrocytes.  Since oligodendrocytes, astrocytes and microglia have all been shown to 
express estrogen receptors, either or both of these scenarios are a plausible mechanism. 
 
Future directions for sex hormone therapy. 
 The study of sex hormones such as estrogen has great potential for treatment of 
neurodegenerative diseases, due to their anti-inflammatory and neuroprotective effects.  
Results from EAE studies indicate that administration of physiologic doses of testosterone 
can ameliorate disease [98] and a recent clinical trial in male MS patients suggests that 
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testosterone therapy has neuroprotective effects, but may not be effective in preventing 
inflammation [85]. Therefore, testosterone treatment in combination with other anti-
inflammatory drugs may represent a good treatment option for male MS patients. 
Testosterone therapy in females is probably not feasible due to masculinizing side effects. 
Our work, combined with that of others, has shown that administration of estradiol is 
effective at reducing demyelination severity in male and female mice.  However, the use of 
estrogen as a treatment in male patients presents the complication of feminization and is 
therefore probably not feasible. Clinical trials in female MS patients suggests that 
administration of a pregnancy level dose of estriol is effective at reducing gadolinium-
enhancing lesions [79].  Although this treatment was well tolerated for the 6 month period of 
the study, longer treatment periods would require the combined administration of 
progesterone, to prevent uterine endometrial hyperplasia [79].     A potential concern with 
using estrogen as a treatment (especially if given in high doses or for prolonged periods) is 
that there could be serious unwanted side effects such as an increased risk of chronic heart 
disease, stroke and breast cancer [284, 285].  Combination therapies with currently used 
immunomodulatory drugs may be beneficial if synergistic or additive effects allowed for the 
use of lower doses of estrogen, which could minimize unwanted side effects.   
Furthermore, the ERβ-selective agonist DPN was shown to reduce EAE symptoms in 
the chronic phase of the disease, and produce significant neuroprotective effects [96].  
Although this compound did not seem to have anti-inflammatory effects or prevent the onset 
of EAE, it may have therapeutic potential in the prevention of axonal and neuronal loss.  
Given in combination with standard anti-inflammatory treatments, ERβ ligands may 
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represent an attractive therapeutic candidate, since many of the growth-stimulatory effects of 
estrogens in breast cancer have been linked to ERα [286].  
The development of therapies that produce the positive effects of estrogen while 
reducing systemic side effects are in high demand.  Selective estrogen receptor modulators 
(SERMs) are molecules with mixed ER agonist/antagonist properties in different tissues and 
represent a promising therapeutic potential.  Several classes of SERMs including 
phytoestroges, tamoxifene, and raloxifene have demonstrated neuroprotective properties in 
vitro (reviewed in [287]). Raloxifene is a nonsteroidal benzothiophene that inhibits the 
growth of estrogen receptor-dependent mammary tumors in rats. It has been classified as a 
SERM on the basis of studies in which it prevented bone loss and lowered serum cholesterol 
levels without stimulating the endometrium [288].  Recently, raloxifene and a raloxifene 
analog, WAY-138923, were shown to reduce incidence, delay onset, and reduce clinical 
symptoms in EAE [93].  These compounds did not alter splenocyte cytokine production from 
EAE mice, but did reduce proliferation of T cells.  Effects on brain cells were not 
characterized in this study.  Raloxifene was also shown to have neuroprotective effects in a 
mouse model of Parkinson’s disease in two out of three studies [289-291] and in an 
excitotoxic injury model [292]. An exciting new avenue of SERM development is underway 
in which in silico techniques are being employed in an effort to develop NeuroSERMS, 
which will target the brain, cross the blood brain barrier, and lack feminizing properties 
[287]. 
 Finally, another potential therapeutic strategy may be to increase production of 
estrogen in the brain.  Aromatase, the enzyme responsible for the conversion of testosterone 
to estradiol, is expressed in subpopulations of neurons in the mammalian brain, and is 
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induced in reactive astrocytes by different forms of brain lesion [229, 293].  Aromatase 
activity reduces neuronal death in neurodegeneratice models in vivo [107, 229, 294-298].  
The aromatase gene is regulated by tissue-specific promoters [299] and therefore it is 
conceivable that selective aromatase modulators could be developed to enhance expression in 
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